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DEVELOPMENT AND VALIDATION OF UPLC/MS/MS METHODS FOR 
QUANTIFICATION OF GANGLIOSIDES IN THE CLINICAL STUDY OF 
GANGLIOSIDE GM3 SYNTHASE DEFICIENCY 
QIANYANG HUANG 
ABSTRACT 
Gangliosides are a large subclass of glycosphingolipids that structurally characterized 
by the addition of mono- or poly-sialyated carbohydrate moieties onto the ceramide 
scaffold. They are presented at significant abundance in the central nervous system of 
vertebrates. Their interactions with trans-membrane receptors, especially receptor 
tyrosine kinase, are believed to play critical roles in modulating signal transduction 
events during cell proliferation, differentiation, migration, and adhesion. Furthermore, 
the disruption and dysfunction on their metabolism have been found to be associated 
with various neurodegenerative disorders, such as Alzheimer disease, Parkinson’s 
disease, and GM3 synthase deficiency. GM3 synthase deficiency (GSD) is a newly 
identified neurological disorder that has been prevalently found in the Amish 
population in the United States. Although the pathological mechanism remains to be 
understood, the condition is severe. It is characterized by infantile onset of severe 
irritability, developmental stagnation, profound intellectual disability and intractable 
seizures. In order to advance our understanding on the etiology of these 
neurodegenerative disorders, especially GSD, analytical assays with sufficient 
specificity, sensitivity, and throughput are urgently demanded to practically assist the 
vi	
	
implementation of relevant clinical studies. In this thesis, three projects have been 
conducted separately to benefit the clinical studies from individual aspects. In project 
1, owing to the increased complexity of molecular assays in screening and diagnosing 
patients affected by GSD associated with increased numbers of identified 
nonsense/missense mutations, we have developed and validated a novel 
UPLC/MS/MS method with promising sensitivity, specificity, and throughput for four 
major ganglioside species, GM2, GM3, GD2, and GD3, in human plasma to facilitate 
the diagnosis and screening of GSD. In project 2, in order to obtain more informative 
results from GSD patients undergoing clinical trial in relation to the development of 
related therapeutic intervention, we have developed and validated a new 
UPLC/MS/MS method in human plasma for quantification of monosialogangliosides 
in combination with DMTMM&PAEA chemical derivatization for analysis with 
superior sensitivity and specificity. In project 3, we have implemented a clinical study 
aiming at developing a therapeutic intervention strategy based on oral administration 
of commercialized ganglioside-enrich formula to the affected patients.  
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CHAPTER Ⅰ 
INTRODUCTION 
 
 
1.1 Gangliosides 
Gangliosides are a large subfamily of glycosphingolipids that abundantly present 
in the central nervous system of living organisms. Up to date, over 180 ganglioside species 
with distinctive structures have been identified in vertebrates [1]. Similar to other 
glycosphingolipid species, they possess hydrophilic carbohydrate moieties being added onto 
the ceramide backbone except for the presence of sialic acid residues, N-Acetylneuraminic 
acid (Neu5Ac), on carbohydrate moieties (Fig.1). This unique combination between the 
hydrophobic ceramide portion and hydrophilic carbohydrate moiety with negatively charged 
Neu5Ac residues confers them distinctive amphiphilic properties, accounting for their 
characteristic behaviors and diverse functionalities in the physiological systems of living 
organisms.  
Gangliosides are generally classified and nomenclated by the degree of 
2	
	
sialylation and the monosaccharide makeup of the carbohydrate moieties. In addition to the 
diversity of their carbohydrate moieties, the presence of long alkyl chain fatty acids with 
variable chain length and saturation degree in the ceramide portion generates an extra 
degree of heterogeneity of their structures [2], implying their physiological versatility in 
regulating the central nervous system of living organisms.      
Gangliosides have been found to be predominantly localized on the outer 
leaflet of plasma membrane of neuronal and glial cells. Generally, they are settled onto the 
cell membrane by embedding their hydrophobic ceramide portions inward into the 
transmembrane section of the lipid bilayer and protruding their hydrophilic oligosaccharide 
moieties outward into the extracellular matrix. This characteristic cell surface configuration 
not only allows the ceramide scaffold to act as a functional lipid anchor to clinch them 
against the cell membrane with a confined orientation in a very secure manner, but also 
enables complete exposure of the oligosaccharide moiety to its surrounding to facilitate 
direct interactions with binding ligands from extracelluar matrix in a very accessible 
environment [3].  
They exert their fundamental functionalities in maintaining integration and 
organizing dynamics of lipid bilayer skeleton primarily by serving as ubiquitous 
components of characteristic regions, known as glycolipid-enriched microdomains (GEMs) 
or lipid rafts, and interacting with other integral membrane components, such as 
transmembrane proteins, sphingomyelins, and cholesterols, on the mammalian cell 
membrane [4]. They present ubiquitously at significant abundance in the central nervous 
system of vertebrates. Mounting evidence has demonstrated that their biosynthesis and 
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metabolism physiologically play pivotal roles for the appropriate development and eventual 
maturation of central nervous system in vertebrate during embryogenesis [5]. Moreover, 
their cell surface expressions and interactions with transmembrane receptors, especially 
receptor tyrosine kinase are believed to be extensively implicated in modulating the signal 
transduction during a wide variety of essential cellular events, including cell differentiation 
[6-8], proliferation [9-12], migration [13-16], and adhesion [17-20]. However, the depletion, 
disruption, and malfunction on their biosynthetic pathway have been illustrated to be 
pathologically associated with the pathogenesis of a number of neurodegenerative disorders, 
including Parkinson’s disease [21-27], Alzheimer disease [28-34], and GM3 synthase 
deficiency [35-37], all of which are neurological syndromes featured by devastating 
neurodegenerative impacts with no therapeutic cures available for effective treatment 
nowadays. Since the etiologies attributed to those currently incurable neurodegenerative 
disorders and the pathological roles played by gangliosides during their pathogenesis have 
not been fully understood, considerable numbers of studies related to this area are currently 
being undertaken towards the complete elucidation of underlying mechanisms by which 
abnormalities on ganglioside biosynthetic and metabolic pathways are etiologically related 
to the development of such clinically devastating disorders.  
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Fig.1 Structures of various sphingolipids.  
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1.2 Gangliosides’ Nomenclature and Classification      
Gangliosides are generally nomenclated by the “two-letter & one-digit” rule 
well-defined by Svennerholm [1]. In this nomenclature system, Svennerholm clearly stated 
that for a particular ganglioside species GXNy, the first letter “G” denotes the word 
“ganglioside”, the second letter “X” serves as a direct indication of the sialylation degree of 
the carbohydrate moiety where “M” represents the monosialylation, “D” represents the 
disialylation, “T” represents the trisialylation, and “Q” represents the quasialylation, and 
the sole digit “N” in this naming system represents different combinations of 
monosaccharide units composing the main carbohydrate chain regardless of the number of 
sialic acid residues attached. In this regard, the number “4” suggests the oligosaccharide 
moiety is solely consisted of β-D-glucose that linked directly to the ceramide portion, the 
number “3” illustrates the oligosaccharide moiety is essentially a disaccharide that 
composed by β-D-glucose and β-D-galactose linked through 2,5-glycosidic bond, the 
number “2” indicates trisaccharide made up by β-D-glucose, β-D-galactose, and 
β-D-N-acetylgalactosamine through two sequential 2,5-glycosidic linkages is the 
oligosaccharide moiety, and the number “1” describes the oligosaccharide moiety is built 
with β-D-glucose, β-D-galactose,  β-D-N-acetylgalactosamine, and β-D-galactose linked 
via three consecutive 2,5-glycosidic bonds to obtain a quasaccharide carbohydrate template 
with highest degree of structural complexity. Furthermore, with this quasaccharide 
carbohydrate template, a number of sialylation sites on the template, including C3 positions 
on two β-D-galactoses and C6 position on β-D-N-acetylgalactosamine, have been made 
available for the sialic acid residue to be physically bound, which necessitates the 
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application of an additional subscript “y” followed by the digit dedicated for the further 
discrimination and classification of GX1 species with sialic acid residues being located 
onto disparate monosaccharide units along the carbohydrate platform. Overall, in 
consideration of all possible combinations and outcomes on their oligosaccharide moieties, 
over 180 ganglioside species with characteristic carbohydrate entities have been identified 
in the vertebrates. Detailed information on their nomenclature is shown in Fig.2.       
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Fig.2 Classification and nomenclature of basic gangliosides. 
Glucose residue: ①; Galactose residue: ②, ④; N-acetylgalactosamine residue: ③; 
N-acetylneuraminic acid residue: ⑤, ⑥, ⑦, ⑧, ⑨, ⑩.   
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In addition to their vast structural diversity from the carbohydrate moieties, the 
amide-bonded fatty acid chain from the C2 position of ceramide backbone also appears to 
possess variable chain length and saturation degree that altering in a very uniform manner. 
The amide-bonded fatty acids from the ceramide portion generally start with the length as 
short as 14-carbon and gradually lengthens in a 2-carbon increment manner to up to 24 
carbons to generate a huge series of long alkyl chain fatty acids with 2-carbon differences 
from each other in the overall profile. The amided-bonded long alkyl chain fatty acids are 
predominantly unsaturated on 16- and 18-carbon species. According to previous studies on 
fatty acid profiling in gangliosides, the individual contribution of a variety of fatty acids 
from the ceramide portion to the total abundance of a single ganglioside species could be 
varying significantly from one sample specimen to another or even the same sample 
specimen at different developmental stages, suggesting differing roles possibly played by 
different fatty acid species in different physiological systems [38]. In combination with 
their structural diversity on the carbohydrate moiety, this variability on the ceramide 
scaffold generates extra degree of structural heterogeneity on gangliosides, conferring them 
with great structural complexity as well as physiological versatilities for the mediation of 
various cellular events in the central nervous system of living organisms. 
 
1.3 Gangliosides’ Biosynthesis 
Gangliosides can be classified into four series, 0-, a-, b-, and c-series, 
corresponding to different degrees of sialyation on the lactosylceramide and disparate levels 
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of complexity on their structures. Simple gangliosides, mostly 0- and a-series, are 
predominantly expressed in normal human tissues during embryogenesis, whereas the 
complex gangliosides from b- and c-series are essentially observed in developing tissues 
during later developmental stages. As demonstrated by Fig.3, the de-novo biosynthesis of 
gangliosides usually starts off with the addition of a glucose residue onto the ceramide 
backbone via the catalysis by ceramide β-glucosyltransferase [39]. Thereafter, the 
glucosylceramide (GlcCer) is converted into the synthetic precursor of four series of 
gangliosides, lactosylceramide (LacCer), through a single-step reaction catalyzed by GlcCer 
β-1, 4-galactosyltransferase (LacCer synthase) [40-41]. Afterwards, specific sialyltransferases 
ST3Gal V (GM3 synthase), ST8Sia I (GD3 synthase), and ST8Sia V (GT3 synthase) catalyze 
the transfer of Neu5Ac residues onto the LacCer scaffold [42], and synthetic LacCer, GM3, 
GD3, and GT3 act as precursors for the downstream biosynthesis along the individual 
pathway following the stepwise manner to generate 0-, a-, b-, and c-series gangliosides, 
respectively, upon the sequential addition of Gal, GalNAc, and Neu5Ac residues onto the 
skeletons from previous synthetic step under the catalysis by the β-1,3-galactosyltransferase 
IV [43], β- 1,4-N-acetylgalactosaminyltransferase I [44], and sialyltransferases ST3Gal II 
[45-47], ST8Sia V [48], or ST6GalNAc III/V[49-50].   
The early biosynthetic stages mainly occur in the cis/median-Golgi, whereas the 
later metabolic stages mostly take place in the trans-Golgi and its corresponding organelle 
network [51]. The activity of glycosyltransferases is specifically regulated by their locations 
on the particular tissue/organ at the transcriptional level [52], leading to their tissue-specific 
gene expressions, which could be exemplified with the essential expression of GM2/GD2 
10	
	
synthase in embryonic tissue and adult brain, whereas the GM3 synthase is universally 
present in all human tissues [53-54]. In addition, post-translational modifications also 
regulate the biosynthesis of four series of gangliosides catalyzed by glycosyltransferase via 
processes including N-glycosylation, phosphorylation, and dephosphorylation, as protein 
kinases A and C are capable of activating the activity of GM2/GD2 synthase while inhibiting 
the others [55-57].   
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Fig.3 The stepwise biosynthetic pathways for four ganglioside series [68]. 
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1.4 Gangliosides’ Interactions with Receptor Tyrosine Kinase (RTK) 
Gangliosides are a big family of mono- and poly-sialylated glycosphingolipids 
that present abundantly at the outer leaflet of plasma membrane of neuron and gial cells. 
They exert the majority of their physiological functionalities by either directly or indirectly 
interacting their carbohydrate moieties, which are being placed on an orientation that is 
protruding outward into the extracellular matrix, with the extracellular domain of a wide 
variety of receptor tyrosine kinases, including including epidermal growth factor receptor 
(EGFR) [58], platelet-derived growth factor receptor (PDGFR) [59-62], fibroblast growth 
factor receptor (FGFR) [63], nerve growth factor receptor (TrkA) [64-66], and insulin 
receptor (IR) [67], as reviewed previously by S. Julien et al. [68]. Receptor tyrosine kinases 
(RTK) are proteins that critically involved in the receptor-mediated biological regulation of 
numerous essential cellular events, such as cell survival, proliferation, differentiation, 
migration, and adhesion. Up-to-date, 58 types of RTKs have been totally identified and 
characterized in humans, all of which are sharing high degree of structural homologies that 
consisting of three characteristic regions, an extracellular domain containing the 
ligand-binding site, a featured transmembrane domain, and a cytoplasmic domain 
containing the entire biological machinery of tyrosine kinase. In general, RTKs are 
activated upon the binding of the ligands to induce the dimerization of the extracellular 
receptor domain, which is usually followed by the subsequent autophosphorylation of the 
cytoplasmic domain on the tyrosine residue to activate the downstream signaling cascade. 
RTKs are predominantly localized in GEMs along with other integral lipid raft components, 
such as gangliosides, choresterols, and sphingomyolins, and associated proteins, such as 
13	
	
integrins, tetraspanins, and plexins, to maintain organization and integrity of the GEMs. 
Within the GEMs, depending upon the expression pattern of gangliosides, cell type, and 
experimental conditions, the signaling of RTKs can be positively/negatively regulated by 
gangliosides through either direct or indirect interactions as summarized in Fig.4 [69-70]. 
Furthermore, alterations on the expression patterns and levels of gangliosides are 
implicated in regulating the activity of RTKs by reorganizing/excluding RTKs from GEMs 
to affect their relative abundance to be presented in GEMs through modifications on 
molecular composition and 3-dimensional structure of GEMs [71-73]. Finally, the presence 
of gangliosides was also demonstrated to be one of the determining factors for the crosstalk 
between RTK subunits and other lipid raft associated proteins to be physiologically 
undertaken and appropriately regulated.  
Based on previous studies, three different mechanisms have been identified 
and described to be critically involved in the regulation of RTKs by gangliosides: the 
regulation on the degree of ligand binding to the targeted receptors by gangliosides as in 
the case of fibroblast growth factor (FGF)/GM1 interaction where the binding of FGF to 
fibroblast growth factor receptor (FGFR) is down-regulated by increased level of GM1, the 
regulation of receptor dimerization as in the case of epidermal growth factor receptor 
(EGFR)/GM3 interaction where the usual dimerization of EGFR upon the binding of 
epidermal growth factor (EGF) is inhibited in the presence of GM3 to prevent the tyrosine 
residue from being subsequently phosphorelated, and the regulation of RTKs activity by 
affecting their localization in GEMs as in the case of IR/GM3 where the degree of insulin 
receptor (IR) delocalization in GEMs is up-regulated to reduce the ligand/receptor 
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interaction by decreasing binding sites from IR available for the binding of insulin in the 
presence of GM3 in GEMs [69, 74]. Generally, these three mechanisms predominantly 
account for the majority of known interactions and pathways through which the signaling 
and activity of RTKs could be potentially regulated by gangliosides. 
 
  
15	
	
 
 
 
Fig.4 Biological regulations on different RTKs by gangliosides [68]. 
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1.5 Ganglioside GM3 Synthase Deficiency (GSD) 
GM3 synthase, or so-called lactosylceramide α-2, 3-sialyltransferase, is a 
ubiquitously expressed protein that is predominantly localized in the Golgi apparatus and 
presented at particularly high abundance in the central nervous system of vertebrates. This 
protein is responsible for catalyzing the enzymatic transferring of Neu5Ac onto the 
lactosylceramide backbone via α-2, 3-glycosidic linkage to generate GM3 ganglioside, 
which is the first step in the de-novo biosynthesis of complex ganglioside species a- and 
b-series as shown in Fig.5. This enzyme is encoded by ST3Gal5/SIAT9 gene which is 
located on chromosome 2p11.2 and composed of 14 exons that encoding a 419 amino acid 
protein in human with minor variance in the amino acid sequence among different species. 
The full-length GM3 synthase protein is found to be containing three characteristic regions, 
a single short transmembrane region and two sialyl motifs, long and short, each of which 
possesses a highly-conserved cysteine residue that has been demonstrated by previous 
studies to be essential for the enzyme to be able to exert its normal catalytic activity for the 
biosynthesis of GM3 ganglioside [75]. 
Recently, a single-nucleotide polymorphism has been identified and described 
in a large Old Order Amish pedigree, which is believed to be associated with an autosomal 
recessive mutation occurred on the GM3 synthase to affect its normal catalytic activity, 
leading to the complete loss-of-function on the enzymatic activity of GM3 synthase and 
thus premature biosynthetic termination of GM3 ganglioside in the individual affected by 
homozygous mutation. Based on previous studies, this autosomal nonsense mutation has 
been found to be geographically located at the exon 8 of ST3Gal5/SIAT9 gene right 
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between the long and short sialyl motifs and genetically associated with a single nucleotide 
substitution on original C base in unaffected individuals to T base in homozygous mutants 
at position 694 of the genome, which predictably switches the original “CGA” codon 
representing the translation of amino acid arginine to mutated “TGA” codon representing 
the immediate termination of the translation machinery, leading to the untranslated short 
sialyl motif on the mutated protein with truncated primary sequence, the complete loss of 
enzymatic capability of catalytically converting lactosylceramide to GM3 ganglioside on 
the functional protein, and thus the premature biosynthetic termination of GM3 ganglioside 
in individuals affected by this homozygous autosomal recessive mutation.  
Unfortunately, as shown by the biosynthetic pathway of gangliosides in Fig.Ⅴ, 
since the biosynthesis of GM3 ganglioside essentially serves as the initial step for the 
stepwise de-novo biosynthesis of more complex a- and b-ganglioside series from 
lactosylceramide, the enzymatic dysfunction on GM3 synthase not only terminates the 
biosynthesis of GM3 ganglioside itself, but also physiologically depletes the formation of 
more complex a- and b-ganglioside series in the biological system of homozygous mutants, 
which has been found to be clinically associated with devastating manifestations as the 
phenotypes accounted for this unique mutation. The syndrome resulted from this autosomal 
recessive mutation has been illustrated by previous studies to be an infantile-onset 
symptomatic epilepsy that characterized by the development of cortical blindness, 
choreoathetosis, flaccid weakness, seizures, profound developmental stagnation, and 
become completely caregiver dependent as its primary clinical outcomes [35, 76-77].  
However, although the evidence on casual role played by altered ganglioside 
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levels in the etiology of this severe infantile-onset neurological disorder and implicate 
genes involved in ganglioside biosynthesis as candidates for causing other related human 
diseases has been well documented, the actual cause on whether the epileptic phenotype is 
attributable to either the physiological deficiency of GM3 and its downstream derivatives 
or the accumulation of ganglioside biosynthetic precursors caused by lack of flux through 
the a- and b-series ganglioside pathways remains to be further elucidated and understood 
by future studies. 
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Fig.5 Ganglioside biosynthesis and GM3 synthase deficiency. 
The darkened box indicates all gangliosides that cannot be synthesized in the absence of 
GM3 synthase.   CGT: Ceramide glucosyl transferase; LCS: LacCer synthase; GM3S: 
GM3 synthase; GD3S: GD3 synthase; GalNAcT: GalNAc transferase. The major 
glycosphingolipid (GSL) are color coded and the major ganglio- (blue; a- and b-series, 
brown; o-series) and alternative globo- (pink) and neolacto- (green) series GSLs derived 
from the immediate precursor, LacCer, are delineated. The a- and b-ganglio series (blue) 
are absent in the plasma of the affected children [35].   
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1.6 Hypothesis 
Due to the lack of effective cure for GSD, the individuals affected by this 
homozygous mutation seem to be continuously suffering from this condition even after our 
current understanding on the disease etiology has been well described and established. 
However, we have always believed that this neurological condition is practically treatable 
from the time it was identified. In fact, we have noticed a very distinguished phenomenon 
that the affected kids appear to be fairly normal for approximately eight weeks after their 
birth, which hints us to speculate that the affected children might have acquired sufficient 
amount of gangliosides from maternal circulation before their birth to make the symptoms 
remain undeveloped during the early age after birth and then gradually develop related 
symptoms after the endogenous gangliosides have eventually been depleted. Based on this 
rationale, it becomes rather reasonable that if we can replace the deficient gangliosides 
caused by this genetic defect in those affected kids with continuous supplement of 
exogenous gangliosides from handful sources, we might be able to correct their 
pathological stigmas and partially or even completely restore the normal ganglioside 
biosynthetic pathway, which might eventually lead to a potential cure.        
So, in the past few years, extensive searching has been performing worldwide 
for the available sources of supplemental gangliosides that are compatible with our 
intended clinical trial. Initially, the animal tissues with relatively more abundant 
ganglioside content appeared to be the most enriched and accessible natural source we 
could find for the study. Therefore, three affected newborns were continuously given with a 
pork brain formula once they were diagnosed with DNA mutation analysis soon after birth. 
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This formula essentially provided approximately 10 mg GM3 per day, with incremental 
amounts given along with their weight gain. Incredibly, all infants being treated showed no 
early signs or symptoms of the disease except hypotonia when they were fed on the pork 
brain formula, although the effects seemed to be not comparably dramatic when the similar 
therapy was conducted on the older children. Unfortunately, all young children involved in 
the study started to develop an allergic reaction against the pork brain formula by 9 months 
of age, thus this pork brain formula-based therapy had to be discontinued on those affected 
kids from that point, and our searching for new ganglioside-enriched supplemental 
products continued to move on.  
In the course of searching for new treatments, we identified a 
highly-concentrated and formulated dairy ganglioside product called G500 manufactured 
by Fonterra in New Zealand. This product primarily contains GM3 and GD3, and has been 
used as a nutritional supplement in normal infants in the previous study [78]. By 
developing a collaborative partnership with this company, the project needs of acquiring 
large-scale nutritional ganglioside-enriched supplement product have become practical and 
feasible for the subsequent clinical studies.  
Considering the promising preliminary results we have observed in the 
younger children fed with pig brain formula, to begin with, we hypothesize that the orally 
administered gangliosides may be adequately absorbed and taken up into the circulation of 
affected patients, and utilized by their metabolic pathway. In addition, we further 
hypothesize that the gangliosides can be delivered across the blood-brain barrier, used by 
the brain of affected patients, and compensate for metabolically deficient gangliosides in 
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their physiological system. Finally, we hypothesize that if the absorption and utilization of 
administered GM3 is a reversible pathological process, some of the manifestations and 
symptoms associated with this neurological disorder might get partially or even completely 
relieved by introducing adequate amounts of GM3 into their body, particularly into the 
CNS, which may potentially lead to a normal life in these children when the exogenous 
GM3 in adequate quantity was given before they started to develop the related symptoms.              
From the perspective of evaluating the effectiveness of new therapy as well as 
the recovery stage of studied patients, it will be very essential to periodically collect bodily 
fluid samples from the physiological circulations of treated patients and accordingly 
implement the quantitative analysis on those collected samples to determine the absolute 
levels of gangliosides presented in their bodily fluids as the most important criteria for 
assessing bioavailability and metabolism of administered exogenous gangliosides from 
G500. Unfortunately, the established quantitative assays with sufficient detection 
sensitivity and specificity to meet the stringent requirements of the clinical study have not 
yet been reported on the literature up to date. As a result, the need of establishing a 
sensitive and reliable quantitative assay dedicated for this study has been urgently 
demanded. 
In addition, based on our current understanding on the disease etiology, this 
disease is essentially an inherited metabolic disorder associated with compromised GM3 
biosynthetic capability and premature endogenous ganglioside depletion, implying the 
pattern of disease progression is very likely to be critically age-dependent and the 
timeframe is one of the most important determining factors pertaining to the success of the 
23	
	
therapy. As a result, younger patient might be subjected to shorter exposure of 
physiological damages associated with premature endogenous ganglioside depletion and 
thus standing a better chance of getting cure and recovered by the proposed therapy, 
enforcing the disease to be ambiguously diagnosed as early as birth. Unfortunately, despite 
the characterization of disease, the prevalence of the disease remains unknown, and we 
believe most of the affected individuals are, with no doubt, under-diagnosed due to the 
complex and time-consuming nature of the DNA mutation analysis. Therefore, a rapid 
quantative method with promising sensitivity, specificity, and ruggedness dedicated for the 
early-on newborn screening and clinical diagnosis of GSD is also in urgent need.      
Hence, the projects aiming at developing quantitative method in human plasma 
for rapid clinical screening and on-birth diagnosis of GSD by UPLC/MS/MS, developing 
highly-sensitive method for quantification of monosialogangliosides in biological fluids 
UPLC/MS/MS, and elucidating the potential efficacy and efficiency of the G500 therapy 
with intended clinical studies by a combination of different methodologies have been 
described in detail in the following chapters.         
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CHAPTER Ⅱ  
DEVELOPMENT AND VALIDATION OF UPLC/MS/MS METHOD IN HUMAN 
PLASMA FOR RAPID SCREENING AND DIAGNOSIS OF GSD 
	
	
2.1 Introduction to Current Diagnostic Method of GSD and High Performance Liquid 
Chromatography Interfaced to Mass Spectrometry (LC-MS) 
Currently, the molecular-based DNA mutation analysis has been the only 
commercially available method for diagnosing individuals affected by this unique nonsense 
mutation associated with the pathogenesis of GSD. Since the time when the etiology and 
pathology of GSD were described by Simpson et al [1] in 2004, with the assistance of the 
molecular-based DNA mutation analysis, more than 50 patients have been diagnosed to be 
affected by GSD from the Amish population around the US. Recently, cases with positive 
diagnosis of GSD affection have also been reported in other populations, including African 
American and European[2,3], suggesting that the actual prevalence of GSD in the US as well 
as worldwide might be much broader than we speculated and have been highly 
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underestimated. As a result, the practical need of implementing a screening and diagnostic 
study has been extremely urgent for the precise determination of actual prevalence of GSD. 
However, based on the GSD cases reported in African American as well as European 
population, it has been discovered that the occurrence of those cases is etiologically 
associated with alternative homozygous nonsense mutation 862C>T located at exon6 of 
ST3Gal5/SIAT9 in European, whereas another homozygous missense mutation 994G>A 
located at exon7 was identified in cases from African American, both of which are known 
to be capable of causing the major enzymatic dysfunction of GM3 synthase. With the 
increased number of mutations that determined to be associated with the pathogenesis of 
GSD, the workflow of molecular-based DNA mutation analysis could be potentially 
complicated, which might significantly reduce the analytical throughput to complete the 
screening and diagnosis of GSD, making this molecular diagnostic technique targeting 
DNA mutation being no longer suitable for implementing this study in a very efficient and 
dynamic fashion. So, the development of alternative methods with desired sensitivity, 
specificity, and throughput has been urgently demanded by this particular study.   
HPLC is a chromatographic separation technique where the sample is forced 
by a liquid at high pressure (the mobile phase) through a column that is packed with a 
stationary phase generally composed of irregularly or spherically shaped particles chosen 
or derivatized to accomplish particular types of separations. HPLC methods are historically 
divided into two different categories based on stationary phases and the corresponding 
required polarity of the mobile phase. Use of octadecylsilyl (C18) and related 
organic-modified particles as stationary phase with pure or pH-adjusted water-organic 
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mixtures such as water-acetonitrile and water-methanol are used in techniques termed 
reversed phase liquid chromatography (RP-LC). The materials such as silica gel as 
stationary phase with neat or mixed organic mixtures are used in techniques termed normal 
phase liquid chromatography (NP-LC). RP-LC is most popularly used technique to 
introduce samples prior to MS detection in LC-MS instrumentation. 
Mass spectrometry (MS) is an analytical technique that measures the 
mass-to-charge ratio of charged particles. It is generally used for measuring masses of 
particles, determining the elemental composition of a sample, and elucidating the chemical 
structures of molecules. In general, MS instrumentations consist of three modules, a 
ionization source, a mass analyzer, and a detector. In this setup, the ionization source 
enables the direct transformation of molecules in gaseous/liquid phase into gaseous ions 
that being detectable by the mass analyzer. Within the mass analyzer, the gaseous ions 
would be separated and analyzed based on their mass-to-charge ratios through a wide 
variety of mechanisms, such as quadrupole mass filter and magnetic mass sector, to allow 
subsequent detection by the detector. In the course of detection, the detector magnifies the 
ion counts into the electronic flow and generates a data set correlates the mass-to-charge 
ratio to the intensity of electronic flow, which is known as mass spectrum.  
Recently, the emerging and advance of electrospray ionization technique, 
which rapidly desolvates and ionizes molecules directed from liquid flow into gaseous 
phase with minimal degree of induced in-source decay, has given rise to the combination of 
HPLC to MS that physically incorporates the separation capabilities of HPLC into the mass 
analysis capabilities of MS to achieve the on-line separation and simultaneous detection of 
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different molecules in very complex sample mixture. With the advent of LC-MS, the 
excellent quantitative perform featured by promising sensitivity and resolution for the 
determination of gangliosides has been enabled to achieve analysis with small sample 
requirement and high throughput. Gu et al. established a method for simultaneous 
quantification of GM1 and GM2 gangliosides in human cerebrospinal fluid using reverse 
phase LC/MS [4]. Sorensen et al. reported a liquid chromatographic approach interfaced 
with tandem mass spectrometry for the quantification of gangliosides GD3 and GM3 in 
bovine milk and infant formula [5].  
However, LC/MS/MS methods established for plasma samples, one of the 
handiest biological samples in terms of collection, with desirable speed of analysis for the 
study has not been reported by previous studies. As a result, in the present work, we have 
developed and validated a UPLC/MS/MS method for the measurement of four common 
ganglioside species including GM2, GM3, GD2, and GD3 in human plasma to facilitate the 
early-on newborn screening and clinical diagnosis of GSD. This assay employs a simple 
protein precipitation strategy for sample extraction, UPLC for chromatographic separation, 
and tandem mass spectrometry in the MRM mode for detection to achieve high sensitivity 
and specificity for rapid analysis. Moreover, due to the limitation of availability of 
analyte-free plasma, a three-level standard addition calibration rather than seven-level 
conventional calibration was utilized to establish the matrix-matched analytical platform as 
required by the FDA for the quantification of small molecules in biological fluids. This 
method has been successfully applied to measurements of these four common ganglioside 
species in plasma samples from normal adults. Considering the sensitivity, specificity, and 
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quickness of this method, we think it is very suitable for the rapid clinical screening and 
diagnosis of GSD as well as other ganglioside-related disorders during the early stage of 
the disease development.     
 
2.2 Materials and Methods 
 
2.2.1 Materials 
Ganglioside standards GM3 and GD3 were purchased from Avantilipids 
(Alabaster, AL). GM2 and GD2 ganglioside standards were obtained from EMD Chemicals 
(Billerica, MA) and Enzo Life Sciences (Farmingdale, NY), respectively. The internal 
standard (IS) N-omega-CD3-Octadecanoyl monosialoganglioside GM3 (GM3-D3) was 
purchased from Matreya LLC (Pleasant Gap, PA). HPLC grade methanol and isopropanol 
were obtained from EMD Milipore (Billerica, MA). Deionized water was prepared through 
the Barnstead Nano-PURE Water Purification System (Asheville, NC). Ammonium acetate 
was from VWR (Bridgeport, NJ).  
 
2.2.2 Human Plasma 
The study was approved by the DDC Clinic Institutional Review Board, and 
written informed consent was obtained from their legal guardians. Clinical information was 
collected when the patients received medical services at DDC Clinic. Human plasma samples 
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were stored at -20℃ before analysis.  
 
2.2.3 Stock and Working Solutions 
Stock solutions of GM2, GM3, GD2, GD3, and IS 2D3-GM3 were prepared by 
dissolving the original materials individually into 80% MeOH to obtain a concentration of 
0.25 mg/ml for each, and were stored at -20 ℃ before use. Three working solutions were 
prepared in 80% MeOH from the stock solutions to obtain ganglioside concentrations as 
following: 3, 13.6, 0.125, 2 µg/ml (WS-QC); 4.5, 20.4, 0.125, 3 µg/ml (WS-1), and 18, 
81.6, 0.5, 12 µg/ml (WS-2) for GM2, GM3, GD2, GD3, respectively. The IS stock solution 
also served as a working solution, named as WS-IS. These working solutions were used for 
preparation of spiked plasma samples as below.  
 
2.2.4 Plasma Sample Preparation 
For method validation, known-concentration samples were prepared by spiking 
ganglioside standards into the analyte-free plasma from patients with GM3 Synthase 
Deficiency. In brief, 30 µL of analyte-free plasma was transferred into each of three 0.6-mL 
centrifuge vials (a, b, and c) followed by individual addition of 10 µL WS-QC to obtain the 
plasma concentrations of 1.00, 4.53, 0.04, and 0.67 g/ml for GM2, GM3, GD2, and GD3, 
respectively. Thereafter, 10 µL of 80% methanol, WS-1, and WS-2 were spiked into the 
vials a, b, and c, respectively. Afterwards, 10 µL of WS-IS was spiked into each of the three 
samples, and this set of samples were named as spiked analyte-free plasma (SAP), Standard 
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Addition 1 (SA-1), and Standard Addition 2 (SA-2), respectively.  
For measurement of the gangliosides in unknown plasma samples from normal 
human subjects, similar procedure as described above was followed except that WS-QC 
was not added. The three samples in each set were named as unknown plasma sample 
(UPS), SA-1 and SA-2, respectively. All the plasma samples were extracted as described 
below prior to LC/MS/MS analysis.  
 
2.2.5 Sample Extraction 
Following the plasma sample preparation, 240 µL of methanol was added into 
each of them followed by vigorous vortexing. Then, the spiked samples were subjected to 
centrifugation at 14,000 G for 15 min at 4 ℃ for protein precipitation. The supernatants 
were transferred into auto-sampler vials with micro-inserts for LC/MS analysis.  
2.2.6 LC/MS Instrumentation 
The UPLC system was composed of a DGU-20A3R degasser, two LC-30AD 
pumps, a SIL-30AC autosampler, a CTO-10A column oven and a CBM-20A system 
controller from Shimadzu (Columbia, MD). The UPLC system was interfaced to a Qtrap 
5500 mass spectrometer equipped with an electrospray ionization source and a built-in 
Valco switch valve from AB SCIEX (Framingham, MA). The Multiple Reaction 
Monitoring (MRM) mode was utilized for quantitation. Data acquisition and 
chromatographic peak integration were conducted using Analysis 1.6.1 software package 
from AB SCIEX.  
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2.2.7 LC/MS/MS Procedure 
After extraction, 30 µl of each sample was injected onto a Kinetex-C18 UPLC 
column (1.7 µm, 50 mm × 2.1 mm; Phenomenex, Torrance, CA) guarded with a C18 
Security Cartridge. The mobile phase was a mixture of 2% MeOH plus 5 mM ammonium 
acetate (A) and MeOH-Isopropanol (1:1) plus 5 mM ammonium acetate (B) using the 
gradient program shown in Table 1. The LC flow at 0.3 mL/min was introduced to the 
waste within the first 2 minutes, and then switched to the mass spectrometer between 2.1 
and 9 minutes while all the monitored ganglioside components were gradually eluted out. 
Afterwards, the LC flow at 0.6 mL/min was directed to the waste again, during which the 
column was cleaned up and re-equilibrated for next run. The column temperature was 
constantly controlled at 35 ℃ during the analysis.  
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Table 1 Optimized UPLC conditions for the separation of gangliosides 
Time 
Minute 
 
B% 
Flow rate 
(ml/min) 
 
Stage 
 
Valco Switch Valve 
0 30 
 
 
0.3 
 
Elution 
 
To waste 1 30 
2 70 
2.01 70 
To MS 
9 95 
9.01 95 
 
0.6 
 
Cleanup 
 
 
To waste 
15.5 95 
15.51 30 
 
Equilibration 
19.5 30 
19.51 30 
0.3 
20.0 30 
A: 2% MeOH + 5 mM Ammonium Acetate 
B: MeOH - Isopropanol (1:1) + 5 mM Ammonium Acetate 
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2.2.8 Calibration Curve 
Quantitation of the gangliosides in the spiked analyte-free plasma (SAP) and 
unknown plasma samples (UPS) was implemented using standard addition calibration 
based on three levels, including one to-be-measured sample with nil addition and two 
standard addition calibrators (SA-1 and SA-2). For each measured ganglioside specimen, 
the total peak area (TPA) was obtained by summing the individual peak area from every 
MRM transition channel in the corresponding sample from a single injection.  
The three-level calibration curve for each ganglioside sample was then 
established by plotting its normalized TPA by the internal standard as y-axis versus the 
plasma concentration of standard addition as x-axis. The linear regression with a weighting 
factor of 1/y2 was employed. The calculation of each ganglioside plasma concentration in a 
sample was conducted using the corresponding equation obtained from the regression line 
as its intercept with x-axis through extrapolation. Exemplified standard addition calibration 
curves for each of the four measured gangliosides from the measurement of healthy 
individuals were shown in Fig.6.  
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Fig.6 Exemplified calibration curves for GM2 (A), GM3 (B), GD2 (C), and GD3 (D) 
from the measurement of a healthy subject.  
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2.3 Results and Discussions 
 
2.3.1 Product Ion Mass Spectra 
The representative product ion mass spectra of D18:1-20:0 ganglioside 
components for the four ganglioside species from added standards were shown in Fig.7. 
Apparently, fragmentation pattern relevance can be observed within GM series and GD 
series, including the common product ions m/z = 274 and 292 for GM series, and m/z = 
290 and 581 for GD series. Owing to their relatively greater molecular masses, the 
singly-charged ions of gangliosides are beyond the detection ranges of our mass 
spectrometer and many other commercially available triple quadruple instruments. 
Therefore, the selection of doubly-charged precursor ions and their appropriate daughter 
ions as MRM transition channels has been necessitated for quantitation in this assay.  
For GD series, two proton-donating carboxyl groups are attached to their sialic 
acid moieties in the carbohydrate portion, the generation of doubly-charged ions had been 
observed to be more favorable in the negative than that in a positive ionization mode. For 
GM series that contain only one proton-donating carboxyl group, the signal responses from 
doubly-charged precursor ions were practically undetectable in a negative ionization mode 
under various conditions we studied during the method development. Since the positive 
mode was found to be more effective in yielding doubly-charged precursor ions from GM2 
and GM3, positive ionization has been selected for determining GM series. 
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Fig.7 The product ion (MS/MS) spectra for D18:1-20:0 components of GM2 (A), GM3 
(B), GD2 (C), and GD3 (D).  
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After evaluating different pairs of precursor → product ions for quantitation, it 
was revealed that the following MRM transitions provided the optimal sensitivity and 
selectivity: [GM2+2H+]2+ → 204, [GM3+2H+]2+ → 274, [GD2-2H+]2- → 290, and 
[GD3-2H+]2- → 290. The fragmentation mechanisms from the precursor to the daughter 
ions have been interpreted and elaborated in Fig.8.  
 
2.3.2 Selection of MRM Transitions 
As known, each ganglioside species include multiple components that share 
the same oligosaccharide moiety but differ in fatty acid chain length within their ceramide 
portion. For accurate quantitation, all the major ganglioside components from each 
ganglioside species with appreciable abundance in the plasma and commercial standards 
need to be detected in the analysis. Therefore, we first carried out a screening study on 
predominant ganglioside components of individual ganglioside species in both normal 
human plasma and commercial standards using the predicted MRM channels through 
LC/MS/MS analysis. The selected MRM transitions corresponding to all the significant 
ganglioside components observed by such analysis for the quantitation of the four 
ganglioside species are listed in Table 2. In addition to the quantitation MRM channels, 
quality assurance MRM channels with transitions from their precursor ions to m/z 274, 292, 
290, and 290 were also employed for GM2, GM3, GD2, and GD3, respectively. Our 
experiments showed that the response ratio for each pair of MRM channels was practically 
constant in standard-spiked solvent and unknown plasma extracts, confirming the identity 
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of the monitored components. The optimized MS parameters for individual analytes are 
given in Table 3.  
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Fig.8 Proposed fragmentation mechanisms for D18:1-20:0 components of GM2, GM3, 
GD2, and GD3 gangliosides. 
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Table 2 The MRM transitions for quantification 
Positive Mode Negative Mode 
Species Component MRM 
Transition 
Species Component MRM 
Transition 
 
 
GM2 
 
 
 
D18:1-14:0 665.1/204  
 
 
GD2 
D18:1-14:0 808.3/290 
D18:1-16:1 678.1/204 D18:1-16:0 822.3/290 
D18:1-16:0 679.1/204 D18:1-18:1 835.3/290 
D18:1-18:1 692.1/204 D18:1-18:0 836.3/290 
D18:1-18:0 693.1/204 D18:1-19:0 843.3/290 
D18:1-20:0 707.1/204 D18:1-20:0 850.3/290 
 
 
 
 
 
 
 
 
GM3 
D18:1-12:0 549.3/274 D18:1-21:0 857.3/290 
D18:1-14:0 563.3/274 D18:1-22:0 864.3/290 
D18:1-16:1 576.3/274  
 
 
 
 
 
GD3 
D18:1-12:0 693.0/290 
D18:1-16:0 577.3/274 D18:1-14:0 707.0/290 
D18:1-18:1 590.3/274 D18:1-15:0 714.0/290 
D18:1-18:0 591.3/274 D18:1-16:1 720.0/290 
D18:1-20:0 605.3/274 D18:1-16:0 721.0/290 
D18:1-21:0 612.3/274 D18:1-17:0 728.0/290 
D18:1-22:0 619.3/274 D18:1-18:1 734.0/290 
D18:1-23:0 626.3/274 D18:1-18:0 735.0/290 
D18:1-24:0 633.3/274 D18:1-19:0 742.0/290 
  D18:1-20:0 749.0/290 
  D18:1-21:0 756.0/290 
  D18:1-22:0 763.0/290 
  D18:1-23:0 770.0/290 
  D18:1-24:0 777.0/290 
  D18:1-25:0 784.0/290 
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Table 3 Optimized MS parameters for individual ganglioside species 
 Positive Mode Negative Mode 
Analyte 
MS Setting 
GM2 GM3 GD2 GD3 
Curtain Gas (Psi) 35.0 35.0 35.0 35.0 
Collision Gas (Psi) High High High High 
IonSpray Voltage (eV) 5400.0 5400.0 -4300.0 -4300.0 
Temperature (℃) 500.0 500.0 600.0 600.0 
Ion Source Gas 1 (Psi) 45.0 45.0 45.0 45.0 
Ion Source Gas 2 (Psi) 45.0 45.0 45.0 45.0 
Declustering Potential (eV) 65.0 65.0 -39.7 -45.7 
Entrance Potential (eV) 7.0 7.0 -10.0 -10.0 
Collision Energy (eV) 25.0 25.0 -50.0 -47.0 
Collision Cell Exit Potential (eV) 20.0 20.0 -23.6 -21.5 
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2.3.3 HPLC Conditions 
Since multiple MRM transitions have been exploited to monitor each of the 
four ganglioside species, a sufficient chromatographic separation between ganglioside 
molecules and plasma interferences is essential to eliminate the potential ionization 
suppression influence from the matrix for the acquisition of high quality quantification 
during the analysis. Based on our preliminary studies during the method development, a 
C18 reverse-phase UPLC column was found to provide the best resolution for multiple 
ganglioside components. Under our optimized LC conditions, all the ganglioside 
components were eluted out and spread within a retention time window from 3 to 9 minutes. 
In general, gangliosides could be strongly retained by the C18 stationary phase due to the 
hydrophobic nature of their ceramide portion. We observed that the use of 
Methanol-Isopropanol (1:1) as the solvent of mobile phase B could elute the gangliosides 
from the C18 stationary phase more effectively than the use of methanol only, and lead to 
shorter chromatographic running time and better peak shapes. The MRM chromatograms 
for the major components of GM3 ganglioside are shown in Fig.9.   
It is noteworthy that the addition of 5 mM ammonium acetate in the mobile 
phases considerably reinforced the peak intensities from all MRM channels in both positive 
and negative ionization modes. This experimental phenomenon can be reasonably ascribed 
to ammonium acetate’s ability to stabilize the pH at neural range, enabling both the 
proton-donating interaction between ammonium group and gangliosides in the positive 
mode and proton-accepting interaction between acetate group and gangliosides in the 
negative mode to be undertaken for the promotion of ionizing efficiency during the 
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electrospray ionization. While ammonium formate or formic acid was added into the 
mobile phases, the responses from positive ionization was enhanced to a certain extent, 
whereas substantial signal suppression was occurred in the negative ionization, which was 
apparently attributable to intensified proton-donating tendency of formic acid and 
ammonium formate as compared with ammonium acetate.   
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Fig.9 Representative chromatograms for major components of GM3 in plasma extract 
from a healthy subject.   
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2.3.4 Sample Extraction Procedure 
The most commonly used method for the isolation of gangliosides from 
biomatrices is a liquid-liquid partition strategy that first reported by Svennerholm and 
Fredman [6]  for the treatment of human brain samples, which has been used or modified 
later by other investigators [7, 8] for extracting gangliosides from milk and other matrices. 
In brief, the workflow is constructed by the steps as following: (a) mixing the biomatrix 
with chloroform/methanol/water (4:8:3) by vigorous shaking; (b) transferring the 
ganglioside-enriched methanol/waster upper phase into a new container without disturbing 
the middle and lower phase; (c) drying the crude extract with inert gas purging, and (d) 
reconstituting the residues with methanol to a certain volume for quantitative analysis. To 
compare the extraction recovery by using our simple protein-precipitation procedure and 
the existed extraction method, we performed a series of parallel studies. In these assays, 
analyte-free plasmas were spiked with the gangliosides followed by extraction with two 
different extraction methods. As expected, our protein precipitation method was not only 
easy-handling and time-saving, but also provided full recovery for all of the four 
ganglioside species (Table 4). In contrast, the reported method generated insufficient 
recovery for GM2 and GM3 gangliosides. According to the literatures, protein-precipitation 
from plasma samples was commonly conducted by the addition of 3 to 4-fold of methanol 
or acetonitrile, followed by high speed centrifugation. However, the widely adopted 
condition generated unsatisfactory recovery of gangliosides from plasma. Based on modest 
polarity of gangliosides from their hydrophilic oligosaccharide moiety and hydrophobic 
ceramide portion, we attempted to achieve the best extraction recovery through adjustment 
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of the polarity by increasing portion of methanol. Nearly 100% extraction recovery was 
achieved for all of the four ganglioside species by the addition of 8-fold methanol into 
plasma for protein precipitation.  
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Table 4 Comparison of extraction recoveries between the reported method and our 
protein-precipitation procedure (n=3) 
Species 
Extraction Recovery (%) 
Protein-precipitation procedure Reported method 
Recovery 
(Mean ± SD) 
(%) 
CV 
(%) 
Recovery 
(Mean ± SD) 
(%) 
CV 
(%) 
GM2 100 ± 8 7.83 66 ± 6 9.70 
GM3 94 ± 7 7.93 41 ± 4 9.12 
GD2 106 ± 9 8.69 103 ± 5 4.46 
GD3 99 ± 5 4.98 102 ± 9  9.23 
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2.3.5 Standard Addition Calibration 
According to the FDA guidelines for bioanalytical method validation [9], the 
same type of matrix as actual samples should be used for the preparation of calibrators and 
QCs during the quantitative method development and validation whenever feasible 
concerning the potential pronounced signal interference imposed by the complex matrices. 
For the determination of exogenous compounds that do not present in intended matrices, 
the conventional standard calibration is usually employed to generate calibration curves 
based on six or more levels of analytes spiked into analyte-free matrices. However, for the 
measurement of endogenous compounds that originally present in the sample biomatrices 
at significant concentrations, the standard addition calibration has been widely used for the 
establishment of matrix-matched calibration. Commonly, each standard calibration curve is 
constructed upon a set of 3-4 different concentrations prepared by addition (including a nil 
addition) of known amounts of analyte standard into aliquots of a sample to be measured. 
Recent publications involving the application of standard addition calibration include the 
quantification of bile acids [10], sialic acids [11], gangliosides [5, 12], and other 
endogenous compounds [13, 14, 15] in various biomatrices. In most of these studies, 
including determination of gangliosides in milk and buttermilk, three or four points were 
used to construct the calibration curves.  
As indicated earlier, one of our objectives for the development of this assay is 
to screen the ganglioside levels in plasma from patients with GM3 synthase deficiency 
during clinical treatments. We have chosen three-level standard addition upon such a 
consideration that these patients are mostly children or even infants, and that they can only 
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provide small amounts of plasma for the study. As shown in Fig.6, the exemplified 
calibration curves had R2 values in a range of 0.9998 - 1 for all four ganglioside species, 
demonstrating a good linear relationship between the analyte response and concentration. 
For the method validation, we prepared known-concentration samples by spiking 
ganglioside standards into aliquots of analyte-free plasma from GSD patients. Analysis of 
such known samples has shown that our assay employing the three-level standard addition 
offered satisfactory precision and accuracy for the measurement of all the four ganglioside 
species in plasma, which is detailed below.  
 
2.3.6 Precision and Accuracy 
The precision and accuracy for both intra-assay and inter-assay were assessed 
by measuring analyte-free plasma samples spiked with the ganglioside standards in 
triplicate. As shown in Table 5, the CV % for intra- and inter-assay of all measured 
ganglioside species was within a range from 0.4 to 6 % with the relative error below 9 %. 
Conclusively, the precision and accuracy of our quantitative method well fulfill the 15 % 
error and variation tolerance as required by the FDA guidelines for bioanalytical method 
validation [9].  
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Table 5 Intra- and inter-assay precision and accuracy for the measurement of 
gangliosides spiked in analyte-free human plasma from GSD patients (n=3) 
 
Species 
Spiked 
conc 
(ug/ml) 
Intra-assay Inter-assay 
Measured 
(Mean±SD) 
(ug/ml) 
Precision 
(CV %) 
Accuracy 
(R.E. %) 
Measured 
(Mean±SD) 
(ug/ml) 
Precision 
(CV %) 
Accuracy 
(R.E. %) 
GM2 1.00 0.99±0.025 2.52 -0.60 1.04±0.059 5.67 4.45 
GM3 4.53 4.45±0.019 0.42 -1.81 4.60±0.156 3.40 1.50 
GD2 0.04 0.05±0.002 3.82 8.45 0.04±0.002 3.27 7.02 
GD3 0.67 0.69±0.043 6.13 3.82 0.70±0.040 5.75 4.35 
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2.3.7 Stability 
The pre- and post- extraction stabilities of gangliosides in plasma under 
various storage conditions were evaluated via the analysis of samples prepared from the 
analyte-free plasma spiked with the gangliosides after undergoing the studied storage 
conditions, and the results are listed in Table 6. The stability of “4-hour pre-extraction 
storage at room temperature” was assessed by spiking gangliosides into the thawed 
analyte-free plasma, letting the spiked samples stand at room temperature for 4 hours, and 
then analyzing the samples via LC/MS immediately following the extraction procedure. 
The stability of “8-hour post-extraction storage at room temperature” was evaluated by 
spiking gangliosides into analyte-free plasma, extracting the spiked samples, letting the 
extracts stand at room temperature for 8 hours, and then injecting them into LC/MS for 
analysis. The measured stability values for the four ganglioside species range from 86 to 
110 % under three different storage conditions, including one month pre-extraction at 
-20 ℃, 4-hour pre-extraction at room temperature, and 8-hour post-extraction at room 
temperature. Apparently, the gangliosides were stable in the plasma at the stages of frozen 
storage, sample treatment, and analysis.  
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Table 6 Stabilities of gangliosides in human plasma under various storage conditions 
(n=3) 
Storage conditions 
Recovery 
(Mean ± SD) 
(%) 
GM2 GM3 GD2 GD3 
One month pre-extraction storage at -20 ℃ 104 ± 9 90.5 ± 8 84.2 ± 5 86.5 ± 4 
4-hour pre-extraction storage at room temperature 96.3 ± 7 98.6 ± 2 86.2 ± 7 88.8 ± 6 
8-hour post-extraction storage at room temperature 101 ± 3 106 ± 1 106 ± 5 110 ± 6 
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2.3.8 Matrix Effect 
The matrix effect for mass spectrometry detection of gangliosides was assessed 
through comparable analysis of analyte-free plasma extracts spiked with ganglioside 
standards and the pure solvent spiked with such standards at the same contractions in 
triplicate. It was found that the matrix impurities substantially suppressed the ganglioside 
signals, and the LC/MS/MS peak areas from the plasma extracts were only 61.3, 36.0, 68.3, 
and 49.0% in comparison to the pure solvent for ganglioside GM2, GM3, GD2, and GD3, 
respectively. By using the standard addition calibration, the matrix effect practically had no 
influence on the measurement because the same matrix was utilized for the calibrators and 
the relevant samples, which was proven by the high linearity of calibration, precision, and 
accuracy. 
   
2.3.9 Method Application 
The validated LC/MS/MS assay has been successfully applied to determine 
ganglioside concentrations in human plasma from different specimens, including 20 normal 
human subjects and 6 GSD patients. As shown in Table 7, the averaged ganglioside levels 
in the plasma samples from 20 normal human subjects (include 12 males and 8 females) 
were 2.37, 9.72, 0.01, and 1.80 µg/ml for GM2, GM3, GD2, and GD3, respectively. In 
contrast, the analyte-free plasma from 6 patients with GSD had no gangliosides presented 
at the measurable level, which was consistent with the pathological manifestation of the 
neurodegenerative disorder. The averaged GM3 concentration in plasma samples from 
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eight healthy human subjects determined by a published LC/MS method [13] was 7.2 
µg/ml, which was quite comparable to our result (9.72 µg/ml).  
 
2.4 Conclusion 
This study detailed the development and validation of a sensitive LC/MS/MS 
method for the determination of gangliosides GM2, GM3, GD2, and GD3 in human plasma. 
This method utilized a simple protein-precipitation procedure for rapid extraction of the 
gangliosides from the matrix, UPLC for high resolution chromatographic separation, and 
multiple MRM transitions for sensitive and specific mass spectrometric detection, which 
had been successfully applied to determine the level of gangliosides in plasma from normal 
human subjects. Considering the quickness, sensitivity, and specificity of this assay, we 
believe that it is also applicable to other potential biomatrices with some appropriate 
modifications.  
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Table 7 The ganglioside plasma concentrations from human specimens 
Subjects Total 
Averaged Levels 
GM2 
(Mean ± SD) 
 (µg/ml) 
GM3  
(Mean ± SD) 
(µg/ml) 
GD2 
(Mean ± SD)  
(µg/ml) 
GD3  
(Mean ± SD) 
(µg/ml) 
Normal Adults 20 2.37 ± 0.79 9.72 ± 3.68 0.01 ± 0.01 1.80 ± 0.64 
GSD Patients 6 NM NM NM NM 
NM – Not Measurable 
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2.5 Future Direction  
The quantitative method established in this study has been known to be the 
first LC-MS/MS method for quantification of gangliosides in human plasma with full 
method validation under FDA guideline for bioanalytical method development. It utilizes a 
simple protein precipitation procedure for the analyte extraction and a matrix-matched 
standard addition calibration based on three levels for the measurement of analytes in the 
plasma matrix. However, a number of factors have practically limited this method from 
being broadly applied into the routine analysis in the clinical laboratory.  
To begin with, depending on the sugar components present in their 
carbohydrate moieties, monosialoganglioside molecules generally have molar mass ranging 
from 1200 to 1600 Da, making the majority of their singly charged molecular ions being 
undetectable by our instrument (dynamic range 50~1250 m/z). Considering carboxyl group 
on the sialic acid residue serves as the sole ionization site on their chemical structures, their 
chances of undergoing dual protonation/deprotonation to generate doubly charged 
molecular ions have been found to be extremely difficult during the electrospray ionization, 
leading to their very low detection sensitivities during the analysis. So, from the clinical 
perspective, this method would be very promising and reliable for clinical diagnosis on the 
screening of ganglioside-related disorders from newborns, but not quite applicable to 
pharmacokinetic studies during the clinical trial where sufficient detection sensitivity from 
the analysis is typically required to draw solid and unarguable conclusions.  
In addition, the clinical study usually requires certain degree of throughput 
from the analytical method to ensure collected samples would be handled in a very timely 
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manner and facilitate the decision-making as well as problem solving. Unfortunately, due 
to the nature of standard addition calibration method, a single sample is required to be 
analyzed repetitively in triplicate for this case in order to establish the calibration curve that 
dedicated for this particular sample, which is extremely laborious and time-consuming, 
making this method more preferable for diagnostic purpose rather than routine clinical 
analysis in terms of analytical throughput.         
Last but not the least, the introduction of protein precipitation strategy for 
sample extraction significantly simplifies the experimental procedure through which the 
plasma sample is processed and reduces the time needed for sample preparation prior to the 
analysis. However, the simplicity of protein precipitation strategy might also adversely 
affect the quality of analysis by retaining the majority of the matrix interferences in the 
plasma extract along with the analyte. As can be seen during the application of this method, 
the increased abundance of matrix interferences in the post-extraction extract tends to 
accumulatively build up on the analytical column over several hundreds of injections and 
thus jeopardize the separation performance over time, leading to the significantly increased 
analytical cost as the column has to be replaced in a more frequent manner.  
As a result, since this method was initially developed and validated solely for 
facilitating the screening and diagnosis of GSD on the upcoming newborns from the Amish 
families, the sample preparation method, chromatographic separation method, and the mass 
spectrometric detection method have been thoroughly simplified in order to accomplish the 
rapidness and efficiency of the analysis according to the time frame needed by clinical 
studies. However, the flip side of this method is that it maintains the analytical quickness of 
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the method while sacrifices the certain degree of the detection sensitivity and specificity, 
which impedes us from further applying this method to answering the major questions 
remaining in the ongoing clinical studies. In order to further overcome those challenging 
issues, improvements on the method performance are needed to take place in order to 
successfully circumvent the major challenges imposed by stringent requirements of clinical 
studies on specificity, sensitivity, and throughput of bioanalytical methodology.  
 
2.6 References     
[1] M.A. Simpson, H. Cross, C. Proukakis, D.A. Priestman, D.C.A. Neville, G. 
Reinkensmeier, H. Wang, M. Wiznitzer, K. Gurtz, A. Verganelaki, A. Pryde, M.A. 
Patton, R.A. Dwek, T.D. Butters, F.M. Platt, and A.H. Crosby, Infantile-onset 
symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of 
GM3 synthase. Nature Genetics 36 (2004) 1225-1229. 
[2] L. Boccuto, K. Aoki, H. Flanagan-Steet, C. Chen, X. Fan, F. Bartel, M. Petukh, A. 
Pittman, R. Saul, A. Chaubey, E. Alexov, M. Tiemeyer, R. Steet, and C.E. Schwartz, A 
mutation in a ganglioside biosynthetic enzyme, ST3GAL5, results in salt & pepper 
syndrome, a neurocutaneous disorder with altered glycolipid and glycoprotein 
glycosylation. Human Molecular Genetics 23 (2014) 418-433. 
[3] K. Fragaki, S. Ait-El-Mkadem, A. Chaussenot, C. Gire, R. Mengual, L. Bonesso, M. 
Beneteau, J. Ricci, V. Desquiret-Dumas, V. Procaccio, A. Roetig, and V. 
Paquis-Flucklinger, Refractory epilepsy and mitochondrial dysfunction due to GM3 
synthase deficiency. European Journal of Human Genetics 21 (2013) 528-534. 
70	
	
[4] J. Gu, C.J. Tifft, and S.J. Soldin, Simultaneous quantification of GM1 and GM2 
gangliosides by isotope dilution tandem mass spectrometry. Clinical Biochemistry 41 
(2008) 413-417. 
 [5] L.K. Soerensen, A liquid chromatography/tandem mass spectrometric approach for the 
determination of gangliosides GD3 and GM3 in bovine milk and infant formulae. Rapid 
Communications in Mass Spectrometry 20 (2006) 3625-3633. 
 [6] L. Svennerholm, and P. Fredman, A procedure for the quantitative isolation of brain 
gangliosides. Biochimica et Biophysica Acta, Lipids and Lipid Metabolism 617 (1980) 
97-109. 
 [7] B. Fong, C. Norris, E. Lowe, and P. McJarrow, Liquid 
Chromatography-High-Resolution Mass Spectrometry for Quantitative Analysis of 
Gangliosides. Lipids 44 (2009) 867-874. 
 [8] K. Ikeda, T. Shimizu, and R. Taguchi, Targeted analysis of ganglioside and sulfatide 
molecular species by LC/ESI-MS/MS with theoretically expanded multiple reaction 
monitoring. Journal of Lipid Research 49 (2008) 2678-2689. 
 [9] Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation, 
US Department of Health and Human Services, FDA, Center for Drug Evaluation and 
Research, Rockville, MD, 2001.  
[10] X. Cai, Y. Liu, X. Zhou, U. Navaneethan, B. Shen, and B. Guo, An LC-ESI-MS 
method for the quantitative analysis of bile acids composition in fecal materials. 
Biomedical Chromatography 26 (2012) 101-108. 
 [11] S.F. Fernando, and B.W. Woonton, Quantitation of N-acetylneuraminic (sialic) acid in 
71	
	
bovine glycomacropeptide (GMP). Journal of Food Composition and Analysis 23 (2010) 
359-366. 
 [12] B. Fong, C. Norris, and P. McJarrow, Liquid chromatography-high-resolution 
electrostatic ion-trap mass spectrometric analysis of GD3 ganglioside in dairy products. 
International Dairy Journal 21 (2011) 42-47. 
 [13] S. McSheehy, L. Yang, R. Sturgeon, and Z. Mester, Determination of Methionine and 
Selenomethionine in Selenium-Enriched Yeast by Species-Specific Isotope Dilution 
with Liquid Chromatography-Mass Spectrometry and Inductively Coupled Plasma Mass 
Spectrometry Detection. Analytical Chemistry 77 (2005) 344-349. 
[14] A. Ciric, H. Prosen, M. Jelikic-Stankov, and P. Durdevic, Evaluation of matrix effect in 
determination of some bioflavonoids in food samples by LC-MS/MS method. Talanta 99 
(2012) 780-790. 
[15] B. Preinerstorfer, S. Schiesel, M. Laemmerhofer, and W. Lindner, Metabolic profiling 
of intracellular metabolites in fermentation broths from β-lactam antibiotics production 
by liquid chromatography-tandem mass spectrometry methods. Journal of 
Chromatography A 1217 (2010) 312-328. 
[16] H.H. Bui, J.K. Leohr, and M. Kuo, Analysis of sphingolipids in extracted human 
plasma using liquid chromatography electrospray ionization tandem mass spectrometry. 
Analytical Biochemistry 423 (2012) 187-194. 
  
72	
	
CHAPTER Ⅲ 
 QUANTIFICATION OF MONOSIALOGANGLIOSIDES IN HUMAN PLASMA 
THROUGH CHEMICAL DERIVATIZATION FOR SIGNAL ENHANCEMENT IN 
LC-ESI-MS 
	
	
3.1 Introduction to Chemical Derivatization Methods for Sialic Acid Neu5Ac and 
DMTMM&PAEA-Based Amidation 
Sialic acids are a big family of N-/O-substituted derivatives of neuraminic acids 
that characterized by the presence of nine-carbon scaffold as their structural backbone. 
Currently, there have been over 43 derivatives from the sialic family identified to exist freely 
in the nature, three of which act as the predominant species in the entire population, 
N-acetylneuraminic acid (Neu5Ac), N-glycolylneuraminic acid (Neu5Gc), and 
2-keto-3-deoxy-D-glycero-D-galacto-nononic acid (KDN). Based on up-to-date knowledge, 
Neu5Ac has been found to be the only sialic acid species that virtually presenting in the 
carbohydrate terminus of glycosphingolipids, especially gangliosides. Their individual 
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chemical structures can be found in Fig.10. Depending on the identity of monosaccharide 
unit to which Neu5Ac is bound, it could be linked with neighboring monosaccharide units 
through either α2-3 or α2-6 linkage in gangliosides. Biologically, sialic acids usually serve 
as a surface clutch at the terminal position of carbohydrate moiety of glycoprotein receptors 
to mediate the intracellular signaling cascade triggered by extracellular ligand-binding 
events. Its biological role in acting as a cell surface regulator to extracellular signaling has 
been prevalently found in a wide variety of essential cellular events, including cell-cell 
recognition [1-3], cell differentiation [4-6], and antigen-mediated immunological response 
[7-9]. 
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Fig.10 Structures of sialic acid Neu5Ac, Neu5Gc, and KDN 
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Owing to its biological versatility in the physiological system, substantial 
studies have been done on the analytical methodology to enable the quantitative analysis of 
this fascinating molecule with promising sensitivity and specificity in various biological 
systems under different physiological conditions in the past decades. However, some of the 
early trials were failed to reach the concentration at which the level of Neu5Ac with 
biological significance could be reliably measured because its highly hydrophilic nature 
makes it fairly easy to interfere with other structural analogs during the analysis. 
Fortunately, the advent of mass spectrometry interfaced to high performance liquid 
chromatography in recent years has given rise to improved sensitivity and specificity of the 
analysis, whereas its mass spectrometric analysis still remain challenging and problematic. 
As a result, a number of derivatization methods have also been developed and introduced to 
practically circumvent the challenges faced by analytical chemist and analytically facilitate 
its mass spectrometric analysis.      
As reviewed previously by Huan, Nie et al [10], the both bound- and 
unbound-Neu5Ac could undergo derivatization to obtain enhanced ionization in its mass 
spectrometric analysis. Particularly, for the analysis of bound-Neu5Ac, same as in the case 
for the analysis of gangliosides, esterification and amidation are two most commonly used 
reactions for the derivatization of Neu5Ac-containing molecules as shown in Fig.11.  
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Fig.11 Structures of sialic acid derivatives [10].  
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In consideration of our urgent demand in significantly enhancing the detection 
sensitivities from monosialogangliosides on the LC-ESI-MS, the amidation reactions with 
the option to attach additional proton acceptors/donors onto the chemical structures of 
monosialogangliosides would thus be a more preferable and advantageous choice over the 
esterification reaction from the sensitivity enhancement perspective. Among multiple 
available options for amidation reactions, 2-(2-Pyridilamino)-ethylamine (PAEA) & 4-(4, 
6-Dimethoxy-1, 3, 5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) amidation 
characterized by simultaneous attachment of two proton-accepting groups following the 
reaction confers the capability of this reaction to convert singly-charged-favorable 
monosialogangliosides to doubly-charged-favorable PAEA-monosialogangliosides in ESI 
positive through a one-step chemical modification, suggesting its tremendous potential in 
resolving this particular problem.  
DMTMM&PAEA-based amidation reaction was first introduced by Shin-ichi 
Endo et al. [11] to derivatize a group of Neu5Ac-containing molecules, including 
3’-sialyllactose, 6’-sialyllactose, and ganglioside GM3, and enhance their detection signals 
in MALDI-TOF. Based on the molecular mechanism of the reaction, DMTMM chemically 
serves as an activator of the carboxylic acid group by forming the DMTMM-Neu5Ac 
active ester intermediate through nucleophilic substitution, which allows the occurrence of 
the subsequent amidation on the esterified carboxylic acid group through another round of 
necleophilic substitution to form an amide bond with the head aliphatic amine group from 
PAEA. The alkaline pyridylamine group at the other end of PAEA confers the capability to 
Neu5Ac residue for undergoing double pronation under either ESI+ or MALDI+ by 
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increasing its ability to capture dual protons during the ionization, which shifts its 
ionization profile from predominantly singly charged to primarily doubly charged in terms 
of its charging pattern. In addition, since the pyridylamine group is less alkaline than the 
alphatic amines group on PAEA, this disparate property on alkalinity gives rise to the 
orientational selectivity on the reaction, which also prevents the further coupling of another 
carboxylic group onto the amidated PAEA. From this study, they have demonstrated that 
multiple times reinforcements on MS responses were observed from PAEA derivatives of 
3’-sialyllactose, 6’-sialyllactose, and ganglioside GM3. Based on their results, the 
DMTMM&PAEA-based amidation was able to be undertaken through a one-pot reaction 
under mild conditions at room temperature with continuous stirring. However, 
unsatisfactorily, the reaction yield they ended up with 3-hour reaction in the 90% 
isopropanol system for 3’-sialyllactose, 6’-sialyllactose, and ganglioside GM3 were 45%, 
60%, and 30%, respectively, which leaves a plenty of room for further improvement on the 
conditions under which the reaction takes place before it could virtually be applied to mass 
spectrometrically analyze the monosialoganglioside from the quantitative standpoint.  
As a result, in the present work, we have developed and validated a new 
UPLC-MS/MS method with enhanced sensitivity for the measurement of three 
monosialoganglioside species (GM1, GM2, and GM3) in human plasma using 
PAEA&DMTMM-based derivatization. The conditions under which the PAEA&DMTMM 
reaction occurs have been re-optimized based on solvent, reaction time, reagent 
concentration, and reaction temperature to achieve above 90% reaction yield for 
monosialogangliosides. This method employed reverse phase UPLC for chromatographic 
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separation and tandem mass spectrometry in the MRM mode for superior detection 
sensitivity and specificity. The ESI-MS responses of the three monosialoganglioside 
species were enhanced by more than 15 times following PAEA&DMTMM-based 
derivatization. We have successfully applied this method to the determination of 
monosialoganglioside levels in human plasma from GSD patients, carriers and normal 
adults.       
 
3.2 Materials and Methods 
 
3.2.1 Materials 
Derivatization reagents 4 - (4, 6 – Dimethoxy - 1, 3, 5 – triazin – 2 - yl) – 4 - 
methylmorpholinium chloride (DMTMM) and 2 - (2 - Pyridilamino) ethylamine (PAEA) 
were purchased from Sigma Aldrich (St. Louis, MO) and Santa Cruz (Dallas, TX), 
respectively. Calibration standards GM1, GM2, and GM3 were obtained from EMD 
Chemicals (Billerica, MA) and Avantilipids (Alabaster, AL). Internal standards (ISs) 
N-omega-CD3-Octadecanoyl monosialogangliosides GM1 (2D3-GM1), GM2 (2D3-GM1), 
and GM3 (2D3-GM3) were purchased from Matreya LLC (Pleasant Gap, PA). HPLC grade 
methanol, acetonitrile, and isopropanol were obtained from EMD Milipore (Billerica, MA). 
HPLC grade formic acid was obtained from Fisher Scientific (Pittsburgh, PA). Deionized 
water was prepared using the Barnstead Nano-PURE Water Purification System (Asheville, 
NC). All materials were used directly without further purification.  
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3.2.2 Human Plasma 
The study was approved by the DDC Clinic Institutional Review Board, and 
written consents were obtained from the study subjects or their legal guardians. The 
genotypes of the studied patients were determined through DNA sequencing and mutation 
analysis. The human plasma samples were stored at -20℃ before analysis. 
 
3.2.3 Stock and Working Solutions 
Stock solutions of DMTMM and PAEA were prepared by dissolving the 
lyophilized powders in 1:1 MeOH/Isopropanol to obtain concentrations of 1 M, and their 
working solutions with concentrations of 100 mM were obtained by serial dilution with 1:1 
MeOH/Isopropanol.  
Stock solutions of GM1, GM2, and GM3 were prepared by dissolving the 
lyophilized powders in 90% MeOH to obtain equal concentrations of 0.250 mg/mL. The 
seven-level working solutions, which also served as calibrators, were prepared though 
serial dilution with 90% MeOH to obtain concentrations of 10.0, 20.0, 50.0, 1.00×102, 
4.00×102, 1.00×103, 2.00×103 ng/mL for GM1, 10.0, 20.0, 50.0, 1.00×102, 4.00×102, 
1.00×103, 2.00×103 ng/mL for GM2, and 80.0, 1.60×102, 4.00×102, 8.00×102, 3.20×103, 
8.00×103, 1.60×104 ng/mL for GM3. The preparation of three-level QC working solutions 
was carried out in a similar manner to obtain concentrations of 25.0, 2.50×102, 1.60×103 
ng/mL for GM1, 25.0, 2.50×102, 1.60×103 ng/mL for GM2, and 2.00×102, 2×103, 1.28×104 
ng/mL for GM3. Likewise, stock solutions of Iss 2D3-GM1, 2D3-GM1, and 2D3-GM3 were 
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prepared by dissolving the lyophilized powders in 90% MeOH to obtain concentrations of 
0.250 mg/mL. The IS working solution was prepared by dilution of the corresponding stock 
solution with 90% MeOH to provide a concentration of 5.00×102 ng/mL for each IS.  
The low plasma QC working solution was prepared by pooling plasma samples 
from multiple GSD patients and dividing the pool into 20 µL aliquots. The high plasma QC 
working solution was prepared by pooling plasma samples from normal adults and dividing 
the pool into 20 µL aliquots.  
All prepared stock and working solutions were kept at -20℃ before use. 
 
3.2.4 Sample Preparation 
For plasma sample, 20 µL of plasma was taken and spiked with 10 µL of IS 
working solution. Afterwards, the spiked samples were subjected to sample extraction 
phase described below.  
For calibration, each of calibrators was prepared by individually mixing 10 µL 
of a corresponding calibrator working solution with 10 µL IS working solution. The 
calibrators were then subjected to sample derivatization phase described below.    
During the sample extraction phase, the spiked plasma samples underwent 
protein precipitation with the addition of 190 µL methanol as described previously [12]. 
The supernatant was transferred into a 1.7-mL plastic centrifuge vial for subsequent 
extraction. Thereafter, 200µL of water and 160 µL of chloroform were added to the 
supernatant. After vortexing, the mixture was centrifuged at 10,000 g for 3 min to separate 
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the liquid into two phases. The upper phase was transferred into a new 1.7-mL centrifuge 
vial. Subsequently, the extraction was repeated twice for the lower phase with 200 µL of 
MeOH and 200 µL of water for each trial, and the extracts were combined and subjected to 
the derivatization phase.     
During the sample derivatization phase, each sample (plasma extract/calibrator) 
was dried under a continuous nitrogen stream, and reconstituted with 40 µL of isopropanol. 
Thereafter, 12 and 48 µL of PAEA and DMTMM working solutions, respectively, were 
added into the reconstituted sample. Then, the reaction mixture was vortexed to mix 
thoroughly, and incubated at 80℃ on the heat block for 40 min. After the incubation, the 
sample vial was removed and placed onto the ice bath to terminate the reaction. Once 
cooled, 100 µL of isopropanol was added to dilute the reacted mixture to a total volume of 
200 µL. Following vortexing, the mixture was centrifuged at 5,000 g for 1 min, and the 
supernatant was transferred into an auto-sampler vial with a micro-insert for LC/MS 
analysis. 
 
3.2.5 LC/MS Instrumentation 
The UPLC system was composed of a DGU-20A3R degasser, two LC-30AD 
pumps, a SIL-30AC autosampler, a CTO-10A column oven and a CBM-20A system 
controller from Shimadzu (Columbia, MD). The UPLC system was interfaced to a Qtrap 
5500 mass spectrometer equipped with an electrospray ionization source and a built-in 
Valco switch valve from AB SCIEX (Framingham, MA). The Multiple Reaction 
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Monitoring (MRM) mode was utilized for quantitation. Individual MRM transitions have 
been given in Table 8. The MS parameters for individual PAEA-monosialogangliosides 
have been given in Table 9. Data acquisition and chromatographic peak integration were 
conducted using the Analysis 1.6.1 software package from AB SCIEX.    
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Table 8 The MRM transitions for quantification of PAEA-monosialogangliosides 
Species 
Collision 
Energy 
eV 
Component 
MRM 
Transition 
Species 
Collision 
Energy 
eV 
Component 
MRM 
Transition 
PAEA- 
GM1 
39.9 
d18:1-14:0 805.6/411.2 
PAEA- 
GM3 
 
 
 
33.0 
 
 
d18:1-14:0 622.9/411.2 
d18:1-16:1 818.6/411.2 d18:1-16:1 635.9/411.2 
d18:1-16:0 819.6/411.2 d18:1-16:0 636.9/411.2 
d18:1-18:1 832.6/411.2 d18:1-18:1 649.9/411.2 
d18:1-18:0 833.6/411.2 d18:1-18:0 650.9/411.2 
d18:1-20:0 847.6/411.2 d18:1-20:0 664.9/411.2 
PAEA- 
GM2 
34.9 
d18:1-16:0 738.7/411.2 d18:1-21:0 671.9/411.2 
d18:1-18:1 751.7/411.2 d18:1-22:0 678.9/411.2 
d18:1-18:0 752.7/411.2 d18:1-23:0 685.9/411.2 
d18:1-20:0 768.7/411.2 d18:1-24:0 692.9/411.2 
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Table 9 MS parameters for individual PAEA-monosialogangliosides 
Analytes 
MS Parameters 
PAEA-GM1 PAEA-GM2 PAEA-GM3 
Curtain Gas (Psi) 30.0 30.0 30.0 
Collision Gas (Psi) High High High 
IonSpray Voltage (eV) 5000.0 5000.0 5000.0 
Temperature (℃) 600.0 600.0 600.0 
Ion Source Gas 1 (Psi) 35.0 35.0 35.0 
Ion Source Gas 2 (Psi) 35.0 35.0 35.0 
Declustering Potential (eV) 83.0 93.0 57.9 
Entrance Potential (eV) 8.1 11.1 12.6 
Collision Energy (eV) 39.9 34.9 33.0 
Collision Cell Exit Potential (eV) 36.0 34.5 32.7 
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3.2.6 LC-MS/MS Procedure 
Following chemical derivatization, 10 µL of sample was injected onto a 
Kinetex-C8 UPLC column (1.7 µm, 50 mm × 2.1 mm; Phenomenex, Torrance, CA) 
guarded with a C8 Security Cartridge. The mobile phases used were a mixture of 2% 
MeOH with 1% formic acid (A) and ACN-MeOH (6:4) with 1% formic acid (B). The 
chromatographic separation was implemented employing a gradient elusion program. 
Briefly, the initial B% was maintained at 50% for 1 min and steeply increased to 75% at 1.5 
min followed by a linear increase to 95% at 7 min. Thereafter, the B% was held constant at 
95% for an additional 1.5 min and then dropped immediately to 50% for remainder of the 
run. In addition, the LC eluent at 0.3 mL/min was directed into the waste during the first 
4.5 minutes and then introduced into the electrospray ionization source from 4.6 to 8.0 
minutes as all derivatized monosialoganglioside components were sequentially eluted and 
detected. Thereafter, the flow rate was increased to 0.6 mL/min to rapidly clean up and 
re-equilibrate the column for the next run. The temperatures of auto-sampler and column 
oven were maintained at 4 and 35℃, respectively, throughout the analysis.  
 
3.2.7 Calibration Curve 
Quantitation of the gangliosides in plasma samples was conducted using 
calibration curves based on seven levels. For each of the three monosialoganglioside 
species, the total peak area was calculated by summing up the IS-normalized peak areas of 
individual components based on a single injection.   
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The seven-level calibration curves were then established by plotting the 
IS-normalized total peak area of each measured monosialoganglioside species as the y-axis 
against the concentration levels of seven-level calibrators as the x-axis. The linear 
regression with a weighting factor of 1/y2 was employed. The calculated equation was 
applied to the measurement of monosialoganglioside levels in plasma sample. The standard 
calibration curves for measured monosialoganglioside species have been shown in Fig.12.  
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Fig.12 Calibration curves for GM1 (A), GM2 (B), and GM3 (C). 
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3.3 Results and Discussion 
 
3.3.1 Derivatization Conditions 
Since the carboxylic acid group on the sialic acid residue bears high preference 
to lose a proton, negative ESI is thus a more common option in generating singly charged 
molecular ions of monosialogangliosides than positive ESI in terms of ionization efficiency. 
However, considering their high molecular weight, the m/z values of singly charged 
molecular ions of major monosialoganglioside species are virtually beyond the detection 
range of many commercially available triple-quadrupole mass spectrometers, including our 
instrument. Therefore, the selection of corresponding doubly charged molecular ions with 
detectable m/z values has been a more practical approach to analyze these molecules with 
such instruments. Based on our preliminary studies, the absence of an additional proton 
donating/accepting group on native structures of monosialogangliosides impedes them to 
undergo the dual proton transferring pathway during ionization, which accounts for the low 
tendency of accepting/donating two protons by monosialogangliosides in ESI and the 
insufficient generation of doubly charged molecular ions in their MS profile, resulting in 
limited detection sensitivity. In order to overcome the limitation, modifications on their 
native structures are needed to increase the efficiency in generating corresponding doubly 
charged molecular ions in ESI.  
The PAEA&DMTMM-based derivatization was first reported by Shin-ichi 
Endo et al. [11] for signal enhancement in the analysis of sialic acid Neu5Ac and 
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ganglioside GM3 using MALDI-TOF. From this study, multiple times reinforcement on 
MS response was observed from the PAEA-GM3. However, it was discovered that the 
derivatization yields of GM1, GM2, and GM3 were extremely poor (< 35%) under the 
reported conditions. In order to overcome this limitation, we optimized reaction conditions 
in terms of reagent concentration, reaction time, reagent ratio, reaction solvent, as well as 
instrumental conditions to achieve a maximal LC/MS peak area from the analytes. As 
shown in Fig.13, we found that 60mM PAEA and 60mM DMTMM provided the maximal 
LC peak area for all measured monosialoganglioside species. In addition, 40min was found 
to be the most favorable time for the reaction. Moreover, in consideration of the reaction 
mechanism, amidation is essentially a typical endothermic reaction with the stringent 
threshold on the temperature under which the reaction is undertaken, suggesting the 
directly proportional relationship between the reaction yield and temperature. Based on this 
rationale, the reaction temperature was optimized to 80 ℃ in accordance to the boiling point 
of the solvent mixture. Under the optimized conditions, the reaction yield was observed to 
be above 90%. With this derivatization, we observed over 15-time signal enhancement 
compared to the previous method [12] due to the abundance of doubly charged molecular 
ions in positive ESI. This beneficial effect could be attributed to the addition of a 
pyridylamine group, a preferable dual-proton acceptor. The reaction scheme has been 
elaborated in Fig.14.      
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Fig.13 Optimization of reaction conditions  
The conditions were optimized based on (A) reagent ratio, (B) reagent concentration, and 
(C) reaction time. 
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Fig.14 Elaborated reaction scheme for PAEA&DMTMM-based derivatization 
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3.3.2 Mass Spec Conditions 
The representative product ion mass spectra of d18:1-20:0 components for 
GM1, GM2, and GM3 were shown in Fig. 3.6. As illustrated by their MS/MS profiles, 
monosialogangliosides appeared to share certain degree of similarities in their 
fragmentation patterns, including common fragments m/z = 411.2 and 573.2, corresponding 
to fragments [PAEA-Neu5Ac+H]+ and [PAEA-Neu5Ac-Gla+H]+, respectively, confirming 
the desired position has been preferentially derivatized. In addition, the universal fragment 
m/z=411.2 was observed to be the most abundant among any other fragments present in the 
MS/MS profiles of PAEA-monosialogangliosides.  
After evaluating the quality of different possible precursor → daughter ion 
pairs for quantitation, we found that the following MRM transitions provided the optimal 
quantitative performance in terms of detection sensitivity and specificity: 
[PAEA-GM1+2H]2+ → 411.2 for GM1, [PAEA-GM2+2H]2+ → 411.2 for GM2, and 
[PAEA-GM3+2H]2+ → 411.2 for GM3. Moreover, transitions [PAEA-GM1+2H]2+ → 
573.2, [PAEA-GM2+2H]2+→ 573.2, and [PAEA-GM3+2H]2+ → 573.2 were also 
monitored for quality assurance. The monitored MRM transitions for quantitation have 
been listed in Table 10. The fragmentation mechanisms for GM1, GM2, and GM3 have 
been interpreted and elaborated in Fig.15. 
In addition, since sialic acid residues are well known to be fragile during 
electrospray ionization, in-source loss of sialic acid residues has been the primary concern 
associated with the analysis of sialic acid-containing molecules employing ESI-MS. 
Therefore, in order to determine the degree of in-source sialic acid loss during ESI, we 
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carried out a series of experiments by individually injecting the derivatized standards into 
the LC and implementing MS full scan on Q3 under our experimental conditions. Based on 
the MS spectra we obtained at the retention times of our analytes (data not shown), the 
amount of PAEA-monosialogangliosides that underwent in-source loss was found to be 
insignificant during the ionization process.   
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Fig.15 The product ion (MS/MS) spectra for d18:1-20:0 components of 
PAEA-monosialogangliosides 
MS/MS spectra for PAEA-GM1 (A), PAEA-GM2 (B), and PAEA-GM3 (C) 
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Fig.16 Proposed fragmentation mechanism for PAEA-monosialogangliosides  
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3.3.3 HPLC Conditions 
Due to the chemical complexity of monosialoganglioside species, an 
appropriate chromatographic separation with one component being resolved and separated 
from another is essential to avoid the competition for ionization between co-eluates and to 
eliminate potential ionization suppression from matrix interferences during analysis. Based 
on our preliminary study, the analytes generally showed good resolution on separation but 
appeared to be overwhelmingly retentive on the C18 stationary phase. This was probably 
due to their elevated hydrophobicity after derivatization, which not only widened the 
chromatographic peak of individual components, but also prolonged the analysis time. In 
comparison, the C8 stationary phase with lower hydrophobicity was observed to retain the 
analytes less vigorously, enabling sharper chromatographic peaks and a shorter LC run 
without sacrificing the separation resolution. The addition of acetonitrile to mobile phase B 
significantly reduced the retention of the analytes on the C8 stationary phase and 
effectively shortened the chromatographic run in comparison with methanol only, leading 
to better peak shape and faster analysis. On the other hand, the certain portion of methanol 
was necessary to maintain the analytes to be solubilized in the mobile phase during the 
analysis. Therefore, the ratio of acetonitrile to methanol was optimized at 6 to 4 for the best 
chromatographic performance. Under our optimized LC conditions, different 
monosialoganglioside components were spread in a chromatographic window from 4.5 to 8 
min. Chromatograms for PAEA-GM3 are shown in Fig.17.  
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Fig.17 MRM chromatograms for different components from PAEA-GM3 
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It is worth noting that the addition of 1% formic acid to the mobile phase 
substantially enhanced the peak intensities from all MRM transitions by multiple times in 
positive ESI. This experimental phenomenon could be reasonably explained by the 
increased proton donating capability of the mobile phase upon the introduction of formic 
acid, allowing the dual-proton acceptance of PAEA-monosialoganglioside to be achieved at 
an elevated level in positive ESI. Expectedly, the reinforcement in MS response was 
observed to be less significant by the addition of ammonium formate and ammonium 
acetate in comparison with formic acid. This was due to their inability to further lower the 
pH of the mobile phase below the level that has been achieved by formic acid.  
In addition, the addition of 1% formic acid into the mobile phase considerably 
reduced the buildup of derivatizing reagents on the column solid phase. This was due to 
enhanced ionization of leftover DMTMM&PAEA, thereby decreasing their retention on the 
stationary phase, resulting in the consistency and reproducibility of separation performance 
from the column over time.            
 
3.3.4 LLOQ, Precision and Accuracy 
The LLOQ, defined as S/N near or above 10, for each analyte was determined 
by analyzing samples prepared from 5 individual lots of plasma spiked with their 
corresponding deuterium-labeled siblings. The LLOQs were 10, 10, and 80 ng/mL for GM1, 
GM2, and GM3, respectively, demonstrating the specificity and sensitivity of this assay for 
the accurate determination of monosialogangliosides in human plasma.       
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The precision and accuracy for intra-assay and inter-assay measurements were 
assessed by analyzing QC standards prepared at three different concentrations in five 
replicates. As shown in Table 10, the coefficient of variation (CV %) and relative error 
(RE %) for intra- and inter-assay measurements were within 9% and 11%, respectively. In 
addition, the precision for intra-assay and inter-assay measurements in the plasma matrix 
was also evaluated by analyzing samples prepared from five individual lots of high and low 
plasma QCs from unaffected adults and GSD patients on a single day and five different 
days, respectively. As shown in Table 11, the CV% from both high and low plasma QC 
measurements were found to be below 15% as required by the FDA guidelines for 
bioanalytical method validation [13].    
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Table 10 Intra- and inter-assay precision and accuracy for the measurement of QC 
standards (n=5) 
Species QC 
Spiked 
Conc 
(ng/ml) 
Intra-assay Inter-assay 
Mean ± SD 
(ng/ml) 
Precision 
(CV %) 
Accuracy 
(R.E. %) 
Mean ± SD 
(ng/ml) 
Precision 
(CV %) 
Accuracy 
(R.E. %) 
GM1 
Low 25.0 27.7±0.90 3.0 11 27.3±1.7 6.0 9.0 
Mid 2.50×102 (2.63±0.18) ×102 7.0 6.0 
(2.74±0.15) 
×102 
5.0 10 
High 1.60×103 (1.43±0.13) ×103 9.0 -11 
(1.58±0.040) 
×103 
3.0 -1.0 
GM2 
Low 25.0 23.4±1.9 8.0 -6.0 25.0±0.60 2.0 0 
Mid 2.50×102 
(2.35±0.099) 
×102 
4.0 -6.0 
(2.42±0.081)  
×102 
3.0 -3.0 
High 1.60×103 
(1.62±0.040) 
×103 
2.0 1.0 (1.67±0.11) ×103 7.0 4.0 
GM3 
Low 2.00×102 
(2.09±0.14) 
×102 
7.0 5.0 
(2.11±0.083) 
×102 
4.0 5.0 
Mid 2.00×103 
(2.06±0.080) 
×103 
4.0 3.0 
(2.06±0.060) 
×103 
3.0 3.0 
High 1.28×104 
(1.26±0.050) 
×104 
4.0 -2.0 
(1.26±0.060) 
×104 
5.0 -3.0 
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Table 11 Intra- and inter-assay precision for the measurement of plasma QCs (n=5) 
Species QC 
Intra-assay Inter-assay 
Mean±SD 
(ng/ml) 
Precision 
(CV %) 
Mean±SD 
(ng/ml) 
Precision 
(CV %) 
GM1 
Low 987±59 6 879±118 13 
High 962±89 9 920±112 12 
GM2 
Low ND N/A ND N/A 
High 308±12 4 302±33 11 
GM3 
Low 54.4±3.0 5 46.7±6.6 14 
High (9.05±0.58) 
×103 
6 (9.65±1.41) 
×103 
15 
Note:  
1. Due to the nature of GSD and reverse phase LC, no ideal low plasma QC was currently 
available for GM1 
2. Each of low plasma QC was prepared from 20m L of patient plasma spiked with 10m L 
of IS work solution 
3. Each of high plasma QC was prepared in a similar manner except the plasma was 
sample from unaffected adult  
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3.3.5 Stability and Extraction Recovery 
Since stabilities of gangliosides in plasma under various storage conditions had 
already been evaluated by our previous studies [12], only the autosampler storage stability 
of PAEA-monosialogangliosides was evaluated in this study by analyzing samples prepared 
from five individual lots of plasma from GSD patients spiked with deuterium-labeled 
standards at QC concentrations before and after overnight storage at 4 ℃. The stability 
values for the three monosialogangliosides were about 100% under such conditions as 
shown in Table 12, indicating no significant loss of any analytes under the storage 
condition of autosampler.            
The extraction recoveries for all monosialogangliosides were assessed by 
comparably analyzing samples prepared from five individual lots of plasma from GSD 
patients spiked with deuterium-labeled standards at QC concentrations in both pre- and 
post-extraction stages. As shown in Table 12, about 80~100% of analytes were recovered 
from the plasma matrix at the studied concentrations, indicating the effectiveness of our 
optimized sample extraction procedure.  
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Table 12 The stability of PAEA-monosialogangliosides and extraction recovery of 
monosialogangliosides from plasma samples at QC concentrations (n=5) 
Species QC 
Spiked 
Concentration 
(ng/ml) 
Autosampler Stability Extraction Recovery 
Mean ± SD 
(%) 
CV 
(%) 
Mean ± SD 
(%) 
CV 
(%) 
GM1 
Low 25.0 103±7.0 7.0 94.0±7.0 8.0 
Mid 2.50×102 101±8.0 8.0 84.0±3.0 4.0 
High 1.60×103 102±3.0 3.0 80.0±2.0 3.0 
GM2 
Low 25.0 104±13 12 84.0±3.0 4.0 
Mid 2.50×102 107±3.0 3.0 83.0±2.0 3.0 
High 1.60×103 100±3.0 3.0 81.0±6.0 7.0 
GM3 
Low 2.00×102 100±10 10 102±4.0 4.0 
Mid 2.00×103 103±5.0 5.0 83.0±8.0 10 
High 1.28×104 100±4.0 4.0 80.0±6.0 8.0 
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3.3.6 Method Application 
The validated method was successfully applied to measure the levels of 
monosialogangliosides in plasma samples from different specimens, including unaffected 
adults, GSD heterozygous carriers, and GSD patients, during the ongoing clinical study. As 
shown in Table 13, the plasma levels of monosialogangliosides from 31 normal adults were 
(1.35±0.39) × 103, (4.71±1.8) × 102, and (9.93±2.9) × 103 ng/mL for GM1, GM2, and GM3, 
respectively. In comparison, averaged monosialoganglioside levels in plasma samples from 
12 heterozygous carriers were (7.12±2.4) × 102, (2.38±1.0) × 102, and (6.23±1.9) × 103 
ng/mL for GM1, GM2, and GM3, respectively, slightly lower than those unaffected 
subjects, which is consistent with results reported by previous studies [14].     
In comparison with plasma concentrations from measurements on unaffected 
adults and GSD patients by the diagnostic method established in chapter 2, the measured 
values of GM3 in plasma samples from unaffected adults determined by the new method 
(9.93±2.9 µg/mL) was found to be comparable with the previous results (9.72±3.68 µg/mL), 
whereas significant variation was noticed from the measured values of GM2 on unaffected 
adults between two different methods (0.47±0.18 versus 2.37±0.79 µg/mL), which could be 
possibly attributed to the physiological variance on GM2 abundance in blood circulations 
of people from disparate populations.     
Interestingly, as a result of the enhanced sensitivity produced by the chemical 
derivatization of monosialogangliosides with DMTMM&PAEA, we detected a significant 
amount of GM3 in the plasma of GSD patients with the newly developed method. As 
shown in Table 3.5, the level of GM3 from 12 of 14 GSD patients (2 patients remained 
106	
	
immeasurable) averaged (1.13±0.33)×102 ng/mL, while the level of GM2 remained 
undetectable. Although the amount of GM3 in the plasma of the GSD patients was small, 
accounting for approximately 1% of plasma abundance of GM3 in the unaffected adults, its 
presence was unequivocal. Since GM3 synthase is the key enzyme involving the initial 
stages of ganglioside biosynthesis, GSD would theoretically result in a complete absence of 
GM3 and all downstream biosynthetic derivatives in these patients [14-16]. Given that a 
fair amount of GM3 was detected in the most affected patients, the question raised from the 
result is where the GM3 comes from. It is possible that the detected GM3 amount may be 
ingested from milk or food or generated from some unidentified ganglioside biosynthetic 
pathways in humans. Apparently the origin of the GM3 in the plasma from GSD patients 
remains elusive and is currently under investigation in our laboratory.  
 
3.4 Conclusion 
This study detailed the development and validation of a sensitive LC-MS/MS 
method for the determination of monosialogangliosides GM1, GM2, and GM3 in human 
plasma via PAEA&DMTMM-based chemical derivatization by using 2D3-GM1, 2D3-GM2, 
and 2D3-GM3 as ISs. In brief, the standards and ISs were rapidly extracted from plasma 
using protein precipitation, cleaned up through liquid-liquid extraction, and derivatized 
under optimized conditions prior to LC-MS/MS analysis. This method employed the UPLC 
system in gradient elution for chromatographic separation and Multiple Reaction 
Monitoring (MRM) for mass spectrometric detection, which has been successfully applied 
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to the measurement of ganglioside levels in plasma samples from GSD patients, carriers, 
and normal human subjects. Regarding its high specificity, sensitivity, and throughput, this 
method could be applicable for therapeutic evaluation and clinical diagnosis of other 
ganglioside-related neurodegenerative disorders in the near future.     
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Table 13 Determination of monosialoganglioside levels in plasma samples from 
different specimens  
Subject Total 
GM1 
Mean±SD 
(ng/mL) 
GM2 
Mean±SD 
(ng/mL) 
GM3 
Mean±SD 
(ng/mL) 
Normal Subject 31 (1.35±0.39)×103 (4.71±1.8)×102 (9.93±2.9)×103 
GSD Carrier 12 (7.12±2.4)×102 (2.38±1.0)×102 (6.23±1.9)×103 
GSD Patient 14 (9.81±3.9)×102 NM (1.13±0.33)×102 
Note:  
1. NM-Not Measurable  
2. Plasma levels of GM2&GM3 below LLOQ were determined by using 20 uL plasma 
sample in conjunction with 10 uL calibrator as described in Section 2.2.4, Plasma 
Sample Preparation.  
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3.5 Future Direction 
In this study, we have developed a novel chemical derivatization-based 
UPLC/MS/MS method for quantification of monosialogangliosides in human plasma with 
superior sensitivity and specificity. Upon the introduction of DMTMM & PAEA 
derivatization method, virtually their first application in quantitative analysis, we have 
successfully enhanced the MS sensitivities of monosialogangliosides by 15~20 times 
compared to other reported methods [12,17], which serves as a very significant 
breakthrough in the field of ganglioside analysis on LC-ESI-MS. More importantly, by 
taking advantages from significantly increased sensitivities from monosialogangliosides 
upon derivatized, we have, in fact the first time, tentatively found the presence of 
endogenous GM3 in the plasma circulation of patient with GSD and promisingly confirmed 
this exciting finding by repetitively analyzing plasma samples from many different GSD 
patients, suggesting that this finding might be acting as a milestone or even foundation for 
future studies related to GSD. Furthermore, with the support from full validation data under 
FDA guideline for bioanalytical method development, this standardized method will be 
quite versatile in fulfilling diverse demands from clinical laboratory and answering 
questions that remain elusive for other ganglioside-related clinical diseases in terms of its 
high sensitivity, specificity, and throughput.  
However, there are still a few aspects for further improvement. Firstly, 
considering the PAEA-ganglioside derivatives are preferably analyzed in ESI positive 
under acid conditions, whereas disialo- and trisialogangliosides are more easily ionized in 
ESI negative under basic conditions, making them practically incompatible with each other 
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for the single-run-analysis. One possible means to circumvent this problem to chemically 
convert mono-, di-, and trisialogangliosides into their corresponding PAEA derivatives at 
comparable degree through a one-pot reaction. Unfortunately, due to the bulky size of the 
pyramiding ring from PAEA, spatial hindrance chemically prevents the DMTMM 
intermediate of both disialo-and trisialogangliosides from undergoing the dual coupling 
with PAEA and makes the formation of di-PAEA- and tri-PAEA-ganglioside derivative 
extremely unfavorable by this reaction as shown by our previous study, which generates a 
great bottleneck for their MS analysis. After numerous trial-and-error studies, we have 
discovered that the one-pot derivatization of mono-, di-, and trisialogangliosides becomes 
feasible only when a structural analog of PAEA with diminished chemical size is used in 
place of PAEA for the amidation reaction, suggesting improved reactivity of 
multisialogangliosides is directly associated with reduced intensity of spatial hindrance 
their DMTMM intermediates experience in the course of the coupling reaction (data not 
shown).        
In addition, based on chemical structures of different gangliosides, 
alpha-carboxylic acid group at the sialic acid residue Neu5Ac of carbohydrate moiety 
might have been the only possible target that can undergo chemical derivatization. 
Unfortunately, since carboxylic acid groups are ubiquitously presented on numerous 
compounds existing in the biological fluid, the chemical selectivity of reactions targeting 
carboxylic acid group has become a very critical challenge for their practical application. In 
this study, although the solvent system of the reaction has been optimized to reduce the 
amount of potential interferences introduced by the plasma matrix and excess quantity of 
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DMTMM&PAEA reagents has been used to maximize the reaction yield, decent degree of 
reduction on the reaction yield has still been observed following in-matrix derivatization. 
This matrix intervention problem becomes even more significant when plasma quantity is 
scaled up for larger-scale analysis. In addition, as the quantities of derivatizing chemicals 
are enlarged in line with the increased matrix intervention from up-scaled plasma sample, 
certain degree of column overload has been observed to cause peak widening and tailing 
from the experiments. As a result, liquid-liquid extraction method might not be a suitable 
option in handling plasma samples with increased scale. Thus, extraction methods with 
greater robustness, such as solid phase extraction, would be needed to process and clean up 
larger scale plasma sample for the analysis in terms of the elimination of matrix 
interferences.     
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CHAPTER Ⅳ  
CLINICAL STUDIES ON PATIENTS WITH GANGLIOSIDE GM3 SYNTHASE 
DEFICIENCY 
	
	
4.1 Introduction to Ganglioside GM3 Synthase Deficiency and G500 Therapy  
GM3 synthase is essentially a ubiquitously expressed protein that is particularly 
abundant in the central nervous system of vertebrates. The primary function of this protein is 
to catalyze the enzymatic transferring of sialic acid residue Neu5Ac onto the substrate, 
lactosylceramide, through the α-2, 3-glycosdic linkage. In human, it is a protein encoded by 
SIAT9/ST3Gal5 gene which is located at chromosome 2p11.2 and composed by 14 exons that 
encode 419 amino acid residues. This protein is characterized by the presence of three very 
distinguished regions on its primary structure, a single transmembrane region spanning across 
the mammalian cell membrane, a long sialyl motif, and a short sialyl motif, all of which are 
found to be essential in order for the protein to exert its normal enzymatic function.   
Ganglioside GM3 Synthase Deficiency (GSD) is an autosomal recessive disorder 
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prevalently identified in the Amish population around the U.S. The primary pathogenesis of 
this unique disorder is etiologically attributed to the inborn-onset metabolic disruption on the 
biosynthetic pathway of gangliosides associated with a homozygous loss-of-function 
mutation occurred on one of the vital enzymes, GM3 synthase, for the de-novo biosynthesis 
of a- and b-series gangliosides. Based on the nature of autosomal recessive inherited disorder, 
a heterozygous carrier of this mutation in general does not have any clinical manifestation as 
an unaffected individual differing only in the level of GM3 within the circulations which 
appears to be slightly (20~30%) lower than the unaffected individual. In contrast to 
heterozygous carrier, the homozygous patient of this mutation suffers severe clinical disease 
as the endogenous biosynthetic GM3 as well as the GM3-derived downstream more complex 
ganglioside a- and b-series have been completely depleted from their physiological systems 
by the genetic defect (Fig.18) [1-4].  
The homozygous loss-of-function mutation accounted for this unique disorder 
has been discovered by Simpson et al. to be a single base substitution pertaining to position 
694 from cytidine to thymine causing a DNA codon shifting from “CGA” arginine codon to 
“TGA” stop codon. Furthermore, the mutation has been mapped on the exon 8 of GM3 
synthase genome, which is located right between the long and short sialyl motifs, leading to 
the unsuccessful translation of short sialyl motif and thus the truncated primary sequence in 
the mutant protein [5].  
A number of studies have documented substantial evidence to demonstrate that 
both long and short sialyl motifs possess a highly conserved cysteine residue to generate an 
inter-motif disulfide linkage that has been found to be essential for the enzyme to preserve its 
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catalytic capability. As the formation of inter-motif disulfide bond was intentionally disrupted 
by substituting the invariant cysteine residue to other amino acid residues with site-direct 
mutagenesis, the ability of the enzyme to transfer and attach sialic acid residue Neu5Ac onto 
the substrate became completely abolished, which sheds a new light not only on elucidating 
the essential role of that cysteine residue in preserving the integrity of the whole enzymatic 
machinery to allow it to perform its regular catalytic duty, but also on facilitating our 
understanding on the development of  disease-related symptoms in terms of the disease 
etiology [6].  
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Fig. 18 Genotyping results from unaffected adult, GSD carrier, and GSD patient [5].  
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As gangliosides are glycosphingolipids playing crucial roles for the development 
and maturation of central nervous system, the lack of gangliosides in human is extremely 
devastating. For children affected by GSD, they would typically develop symptoms like 
severe irritability, failure to thrive, profound developmental delay, and retractable seizure 
before 6 months of age. By early childhood, the majority of affected patients will start having 
cortical blindness, choreoathetosis, flaccid weakness, seizure, profound physical and mental 
retardation, and become completely caregiver dependent. For years, due to the practical 
limitations in adequately in-vivo modeling this neurological disorder, particularly in mice, as 
mice might have a completely different ganglioside metabolic pathway from human, the 
GM3 synthase knockout mice have been discovered to have essentially normal phenotypes 
[7]. So, the effective treatment on this devastating condition remains highly undeveloped and 
the progress on its discovery has been significantly slowed.            
However, we have always believed that this is a very treatable neurological 
condition from the time we identified it as we noticed that the affected children appear to be 
fairly normal for approximately eight weeks after their birth, which clues us to speculate that 
the affected children might have acquired sufficient amount of gangliosides from maternal 
circulation before their birth to make the symptoms remain undeveloped during the early age 
after birth and then gradually develop related symptoms after the endogenous gangliosides 
have eventually been depleted. Based on this rationale, it becomes rather plausible that if we 
can replace the endogenous gangliosides in deficient caused by this genetic defect in those 
affected kids with continuous supplement of exogenous gangliosides from handful sources, 
we might be able to correct their pathological stigmas and partially or restore their normal 
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ganglioside biosynthetic pathway, which might eventually lead to a potential cure. 
So, in the past few years, we have been searching extensively for the available 
sources of supplemental gangliosides that are suitable and affordable for our intended clinical 
trial. Initially, the animal tissues with relatively more abundant ganglioside content appeared 
to be the most enriched and accessible natural source we could find for the study. Therefore, 
three affected newborns were continuously given with a pork brain formula once they were 
diagnosed with DNA mutation analysis soon after birth. This formula essentially provided 
approximately 10 mg GM3 per day, with incremental amounts given along with their weight 
gain. Incredibly, all infants being treated showed no early signs or symptoms of the disease 
except hypotonia when they were fed on the pork brain formula, although the effects seemed 
to be not as much dramatic as the similar therapy was conducted on the older children. 
Unfortunately, all young children involved in the study started to develop an allergic reaction 
against the pork brain formula by 9 months of age, thus this pork brain formula-based therapy 
had to be discontinued on those affected kids from that point due to the complexity of brain 
tissue matrix.  
In the course of searching for new supplements, we identified a 
highly-concentrated and appropriately formulated dairy ganglioside product, called G500, 
manufactured by Fonterra in New Zealand. This G500 product is consisted of high levels of 
GM3 and GD3 purified from natural sources, which has been formulated and commercialized 
into a form of integral infant formula to make it suitable for direct oral administration on 
daily basis with minimal restrictions. This formula has been successfully used as a nutritional 
supplement in normal infants, which showed almost no signs of triggering immunological 
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responses on studied infants at given dosage in the previous study [8]. With the development 
of this newer generation of GM3&GD3-enriched infant formula, the continuous 
supplementation of highly-pure and -concentrated gangliosides on those affected kids has 
been made practical and feasible for treating this neurological disorder from the long term 
perspective. Furthermore, by developing a collaborative partnership with this company, we 
have been able to obtain sufficient amount of G500 product at no financial cost and fulfill the 
large-scale need on this G500 product from this project for the subsequent clinical study.   
Based on the promising preliminary results we have observed in the younger 
children fed with pig brain formula, with continuous oral G500 supplementation on daily 
basis, we first expect that the orally administered gangliosides from G500 may be adequately 
absorbed and taken up into the circulation of affected patients, and utilized by their metabolic 
pathway. In addition, the gangliosides provided by G500 are also expected to be delivered 
across the blood-brain barrier, used by the brain of affected patients, and compensate for 
metabolically deficient gangliosides in their physiological system. Finally, we hypothesize 
that if the absorption and utilization of administered GM3 is a reversible pathological process, 
some of the manifestations and symptoms associated with this neurological disorder might 
get partially or even completely relieved by introducing adequate amounts of GM3 into their 
body, particularly into the CNS, which may potentially lead to a normal life in these children 
when the exogenous GM3 in adequate quantity was given before they started to develop the 
related symptoms. 
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4.2 Materials and Methods 
 
4.2.1 Overall Approaches 
The study design is fairly straightforward. We orally administered an adequate 
amount of GM3 and GD3 gangliosides from G500 to the children with GM3 synthase 
deficiency and assessed them clinically, and monitored them biochemically, particularly 
focusing on bioavailability and metabolism of gangliosides, and the gangliosides’ therapeutic 
effects on the intellectual disability in this condition. Since there is no endogenous 
ganglioside synthesized in these patients, the study design is overly simplified in many ways. 
For instance, if a detectable level of gangliosides is found in the patients’ plasma and 
cerebrospinal fluid, our main hypotheses, that the orally administered gangliosides may be 
adequately absorbed, taken up into the circulation, and cross the blood-brain barrier, are 
confirmed. Further studies will be focusing on clinical assessments of these patients to 
determine if the orally delivered gangliosides are therapeutic. 
 
4.2.2 Quantitative Analysis on Gangliosides by LC/MS/MS  
As our study is designed to determine the bioavailability and metabolism of 
administered gangliosides provided by G500 in the affected patients, we are in an urgent need 
to have a reliable and sensitive analytical assay on hand in order to periodically monitor and 
quantitative determine the levels of administered gangliosides to be absorbed by the 
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physiological circulations of studied patients. As a result, the established UPLC/MS/MS 
method from chapter 3 will be used in combination with the chemical derivatization protocol 
as the primary means for implementing the intended study on collected plasma samples.  
In addition, as an alternative means to confirm the positive existence of GSD 
disease on newborns screened and diagnosed by DNA mutation analysis, the UPLC/MS/MS 
method described in chapter 2 will be serving as the secondary confirmatory technique to 
rapidly assure the positive existence of targeted mutation by quantitatively looking at the 
levels of endogenous GM2, GM3, GD2, and GD3 in plasma samples collected from 
diagnosed patients prior to embarking on the G500 therapy.  
 
4.2.3 Subjects of the Study 
5 patients with GM3 synthase deficiency aged from birth to 26 years old were 
recruited into this study and divided into two separate groups, control (n=2) and treated (n=3) 
group. We plan to include as many younger patients as possible, particularly the patients 
under 2 years old, as the shorter time period of exposure to this condition in the younger 
patients might cause less brain damage, thus may lead to more dramatic and positive clinical 
outcomes. Since contraception is against the Amish religious belief, we expect more 
newborns with GM3 synthase deficiency will be coming in into these affected families, who 
are going to be receiving an immediate and continuous treatment with G500 and thus 
hopefully preventing the disease progress to a level at which the normal life can be brought 
back once again in these new patients.  
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4.2.4 Assessments 
For this study, each patient is expected to receive oral ganglioside administration 
for at least 12 months. Formal clinical evaluations and ganglioside measurements are 
performed periodically before and during the study. The comprehensive clinical evaluations 
performed include: 1) a comprehensive examination with a list of clinical parameters for each 
patient by the PI and a pediatric neurologist (the pediatric neurologist will be single-blinded 
as the participation information is not available to him); 2) developmental assessments, 
including Battelle Developmental Inventory (2nd edition) by the developmental psychologist.  
 
4.2.5 Dosage and Ganglioside Monitoring 
The amount of the gangliosides to be administrated remains to be determined. 
We estimate that 120 mg dietary ganglioside may be needed to have 2.4 mg (2%) reaching to 
the brain. This amount can be delivered through 10 ml of Ganglioside 500 (G500), which 
contain 50 mg GM3, 60 mg GD3 and trace amounts of other gangliosides. We expect that the 
needs for gangliosides might be bigger at the start as the patients are in complete depletion 
status for GM3 and its downstream derivatives. We will closely monitor the plasma 
ganglioside level and increase the dosage as needed until the plasma GM3 level becomes 
reasonably stable and close to the level of the low range of normal heterozygous controls.  
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4.2.6 Data Analysis 
Since there is no endogenous ganglioside synthesized in these patients, the data 
analysis is fairly easy and straightforward. In comparison to the levels of gangliosides in 
patients’ plasma and cerebrospinal fluid at the pre-dosed stage, if detectable or increased 
levels of gangliosides are found in their biological circulations after being dosed with G500, 
our hypotheses are confirmed. Further data analysis will focus on the comparison of clinical 
assessments of these patients before and during the study to determine if the orally delivered 
gangliosides are therapeutic. 
 
4.3 Results 
 
4.3.1 Assessment on Physical Development 
Owing to the infantile-onset trait of GSD on patients affected by the homozygous 
mutation, they in general begin to develop symptoms like severe irritability, failure to thrive, 
profound developmental delay, and retractable seizure before 6 months of age and more 
deteriorating symptoms like cortical blindness, choreoathetosis, flaccid weakness, seizure, 
and profound physical and mental retardation by early childhood. So, the inborn-onset 
symptoms associated with retarded and dysfunctional development on a variety of physical 
parameters, such as body weight, body length, and head circumference, could not only act as 
a direct and straightforward indicator for the severity of the disease progression on affected 
children, but also able to serve as a characteristic marker for the early-on evaluation of 
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delivery strategy as well as therapeutic effectiveness of G500 formula to the administered 
patients during the ongoing clinical trial.  
From the standpoint of evaluating the progression of disease severity in terms of 
the degree of improvements on the physical development, the virtual values of a number of 
physical parameters, including body weight, body length, and head circumference, have been 
acquired in 6-month window along the ages of affected children to obtain the growth trend 
and tendency regarding their physical development in comparison with the unaffected 
children. As shown in Fig.19, compared to the unaffected kids, the typical physical 
development of patients with GSD initially appears to be fairly normal in the first few weeks 
after birth, starts to develop moderate delaying symptoms in next a couple of months, and 
becomes progressively severe in terms of retardation associated with their increasing age, 
which consistently matches the expected clinical outcome of GSD with age-dependent and 
stage-specific severity as described previously. 
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Fig.19 The disease progression in relation to the patient age  
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For the purpose of evaluating the delivery strategy as well as the therapeutic 
effectiveness of the G500 formula, the actual values of physical parameters, including body 
weight, body length, and head circumference, have also been acquired on 3-month basis from 
affected children in two separate groups, control and treated group, along their ages to 
establish the pattern of overall physical development compared to unaffected kids in response 
to the G500 therapy. As illustrated by Fig.20, the individual from control group (A) with no 
access to G500 treatment exhibited significant deviations on the growth patterns from the 
normal growth curves in all studied aspects, especially for growths after 6-month post-birth, 
which can be similarly predicted from we have seen previously from other untreated patients. 
However, based on the growth curves we have obtained from individuals (B&C) in 
G500-dosed group, compared to the control group without receiving the G500 treatment, they 
showed approximately 20~30% improvements on their physical developments and being 
more mathematically correlated towards the growth pattern of normal individuals regarding 
almost every single aspect in response to G500 therapy.   
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Fig.20 Growth charts for individual patients 
Results of physical examination for (A) patient with GSD; (B) patient with GSD on G500; (C) 
patient with GSD on G500, and the arrow bars are indications of specific time points at which 
the therapy was initially started. 
A 
B C 
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4.3.2 LC/MS/MS Analysis 
Due to the ease of sample handling and collection, we have been continuously 
analyzing plasma samples collected from different patients at various time points to monitor 
the possible changes on ganglioside levels within the blood circulation of GSD patients 
before/after the dosage of G500. As we previously speculated, if the administered GM3 and 
GD3 from G500 indeed gets absorbed and utilized by the physiological system of patient to 
reactivate the compromised biosynthetic pathway of downstream GM3-related derivatives, 
the blood system would be the primary circulation that those absorbed gangliosides rely upon 
to get spread out and delivered across the entire physiological system of the patient. 
Therefore, the levels of gangliosides in the blood circulation following the G500 treatment 
are expected to be continuously increased as the therapy goes on and on, which is also 
consider as another important indicator of the successful administration and absorption of 
G500-derived gangliosides during the clinical study.  
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Fig.21 Levels of circulating monosialogangliosides in the plasma samples of GSD 
patients determined by LC/MS/MS 
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Practically, the analysis on plasma samples collected from patients based on a 
regular 3/4-month interval has been carried out by employing the LC/MS/MS method 
established in chapter 3, and a portion of the quantification results have been shown 
individually in Fig.21. As can be seen from Fig.21, the patients currently undergoing 
treatment generally show irregularly fluctuated pattern on the level of circulating GM3 from 
80~200 ng/ml in their plasma samples in response to the progression of G500 therapy, while 
the level of circulating GM2 remained consistently undetectable throughout the entire study, 
which is contradicted against our hypothesis that as the changes on circulating GM3 level in 
plasma turned out to be insignificant in comparison with the pre-dosed plasma level and 
inconsistent with what has been expected from longterm continuous exposure of orally 
administered G500 under normal physiological conditions, possibly accounting for the 
absence of circulating GM2 in the patient’s plasma sample with insufficient synthetic 
precursor, GM3.     
Moreover, regarding the circulating GM1 whose level represents the 
combination of total concentration from two predominant co-existing subspecies, GM1a and 
GM1b, the concentration values presented here on GM1 are relatively less informative than 
GM2 and GM3 levels for this particular study as GM1a itself belongs to the family of 
GM3-derived downstream derivative, whereas endogenous GM1b is mainly synthesized by a 
different precursor through a GM3-independent pathway. Based on the disease etiology as 
well as the biosynthetic pathways they are involved, GM1a is expected to undergo premature 
biosynthetic termination and possess consistent behavior with circulating GM2 to remain 
completely absent from patient plasma samples during the analysis. However, the 
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biosynthesis of GM1b is expected to be highly up-regulated in order to relieve the 
accumulation of lactosylceramide in the body by fluxing the accumulated lactosylceramide 
through the pathway. 
 
4.3.3 Assessment on Intelligential Development    
Based on the disease pathology described by previous studies [1-4], one of the 
typical symptoms closely associated with the progression of GSD is the profound mental 
development retardation, a common and characteristic clinical manifestation to the majority 
of neurodegenerative disorders affecting the maturation of central nervous system (CNS), 
which is a critical step in maintaining the development of intelligence and brain functions at 
regular pace. In the absence of endogenous GM3 as well as its downstream complex 
metabolites, all of which are indispensable molecular valves ascertaining the CNS is 
appropriately matured and regulated, development of normal intelligence and brain functions 
have been demonstrated to be severely compromised under this particular physiological 
condition. From this regard, the extent to which the intelligential development has been 
virtually improved before/after G500 therapy could certainly be used as one of the primary 
clinical indicators to establish the logical correlation between the therapeutic effectiveness of 
administered G500 and progression of GSD.     
The results of intelligential development assessment from two affected patients 
have been summarized and shown in Fig.22. In Fig.22, parameters related to intelligential 
development have been determined in parallel studies between the G500-treated and 
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untreated patients before/after the intervention at comparable timelines, and the measured 
values have been normalized to standard levels to evaluate the potential impact of 
administered G500 in terms of clinically improving their intelligential activities along the 
therapeutic intervention. As illustrated by Fig 4.5, in comparison with untreated patient who 
in general possesses minimally developed or even highly undeveloped physical behaviors 
pertaining to his/her intelligential development at the age of 24-month, pretreated patient 
overall displays more progressive trends of development on intelligence except for fine motor 
at the age of 26-month. However, as the pretreated patient embarking on the therapeutic 
intervention, significant degree of behavioral improvements have been observed in aspects 
like self care and self conception, whereas minor improved or even reduced levels of 
intelligential activities have been observed in other studied criteria on treated patient 
compared to the untreated one at the age of 42- and 41-month, respectively.  
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Fig.22 Comparison on intelligential development assessment between one control and 
one treated patients before(A)/after(B) the therapeutic intervention  
  
A 
B 
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4.4 Discussion 
 
4.4.1 Assessment on Physical Development 
Based on Fig.19, one very interesting observation to note is that children affected 
by GSD generally have comparably normal clinical behavior and developmental trend at the 
time of birth, which could be primarily ascribed to their continuous absorption of exogenous 
a- and b-gangliosides via maternal circulation during embryogenesis due to their incapability 
of endogenously synthesizing a- and b-gangliosides on their own, confirming part of our 
hypothesis that the homozygous affected babies receive the major source of supplemental 
gangliosides from their heterozygous mothers for being able to maintain the regular pace of 
their development at the pre-natal stage. However, as the maternal provision on supplemental 
gangliosides has been physically terminated from them after birth, their circulating a- and 
b-gangliosides start to undergo gradual depletion from their bodies, which is usually 
accompanied by the gradual development of typical early signs of neurodegenerative 
disorders, particularly seriously delayed physical development. Moreover, the developmental 
retardation directly corresponding to the disease progression becomes increasingly severe as 
their demand in obtaining molecules of GM3 and its downstream derivatives gets 
progressively urgent with increasing age, which is also complied with our previous 
predictions on the further development of other complex symptoms associated with this 
clinical condition, suggesting that the severity of physically developmental retardation is 
essentially a good clinical marker for the evaluation of age-dependent and stage-specific 
progression of this unique syndrome.  
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In Fig.20 (A), a typical progressive developmental stagnation pattern following 
age-dependent manner has also been described in terms of three variables, body weight, body 
length, and head circumference, from a 3-year old boy affected by GSD. As shown by the 
growth charts from Fig.20 (A), the physical growth of this boy appears to be fairly normal in 
the first 6 months after birth, falls out from the reference ranges of normal growth in 
following months, and continues to stay degenerately deviated from the normal curves for the 
rest of the studied period, which is consistent with the result from Fig.19.  
However, in the presence of G500 therapy, another 3-year old boy affected by 
GSD who starts off the initial G500 intervention at the age of 12-month, as described in 
Fig.20 (B), has undergone significant improvements on his physical development to boost his 
falling growth curves back into the reference ranges in terms of body weight and head 
circumference after the existing gangliosides received from maternal circulation have been 
thoroughly depleted from his body, suggesting that those exogenous gangliosides provided by 
G500 formula have somehow been absorbed and utilized by his physiological system to 
replace the missing gangliosides from the metabolic pathways, reactivate the metabolism and 
biosynthesis of a- and b-ganglioside series, and thus facilitate his physical development from 
the early stage, which closely matches a portion of our hypothesis that the orally administered 
gangliosides from G500 could be absorbed by the patient’s physiological circulations and 
utilized by the biosynthetic and metabolic pathways to make more complex downstream 
derivatives.  
Likewise, based on the growth curves from another 18-month old girl affected by 
GSD, who embarks on the G500 intervention at the age of 6-month, as described in Fig.20 
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(C), she has displayed a full spectrum of significantly improved growth curves well above the 
minimal cutoff of the reference ranges. More importantly, compared to the previous 
36-month old boy, she has showed even more significant improvements on her physical 
development in all studied aspects when the intervention was initiated 6-month earlier, 
suggesting that affected children with younger age might receive less serious damage to their 
body from the metabolic disruption and depletion as they suffer shorter exposure to 
ganglioside deficiency in terms of timeframe and thus are more sensitive and responsive to 
the G500 intervention than the older ones. Namely, the earlier those affected children begin to 
receive the G500 intervention, the better chance they stand of possibly getting more 
effectively treated by the G500 therapy, confirming some of our hypothesis on treatment 
implementing strategy.     
 
4.4.2 LC/MS/MS Analysis               
In Fig.21, quantitative results from three patients with GSD receiving G500 
therapy have been selected to represent the entire treated group and demonstrate the potential 
changes on monosialoganglioside levels in patient’s plasma circulation in response to the 
daily G500 administration. Based on the plasma concentration levels of 
monosialogangliosides presented in Fig.21 (A), the circulating GM3 level unexpectedly 
vibrates up and down along the baseline value in a very irregular pattern in response to the 
G500 intervention, whereas the circulating GM2 level remains constantly undetectable during 
the analysis, suggesting the possibilities of either inefficient absorption of exogenous GM3 
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and GD3 from G500 by blood circulation through oral administration or the rapid 
flux-through of absorbed GM3 and GD3 on the metabolic intermediates by the over-active 
enzymes for the biosynthesis of complex ganglioside molecules at the terminal of the 
pathway. In comparison with circulating GM2&3 levels, level of circulating GM1 seems to 
be not quite indicative as this concentration value represents essentially the sum of 
concentrations from two co-existing positional isomers, GM1a and GM1b, both of which are 
essentially GM1 gangliosides with the sialic acid residue being placed at disparate positions 
and appear to have completely opposite behaviors in the course of G500 treatment and 
disease progression, leading to unpredictable consequence based on alterations on total GM1 
concentration during the current study.  
Likewise, based on quantification results we have observed from patients in 
Fig.21 (B) & (C), the levels of GM1&2&3 have been found to possess similar quantitative 
behaviors in the plasma circulation of other patients as we have seen previously, which could 
be potentially used as a representation to gain the general picture on patient’s overall response 
to the ongoing G500 intervention implemented through oral administration at the blood 
circulation level. However, due to the possible actions of either aforementioned reasons or 
even the combination of both, from this study, we failed to quantitatively observe the 
outcome of major increases on the levels of metabolic intermediates along the pathway in the 
blood circulation of patients dosed with G500 as we expected, which might require a more 
robust analytical method that is capable of including more downstream derivative species 
onto the quantification list and further identify the actual cause that is responsible for this 
undesirable outcome. Unfortunately, owing to the practical limitations we have encountered 
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from the analytical instrumentation as well as the methodology, the method with the ability to 
simultaneously quantify a full panel of analytes of our particular interest from the metabolic 
pathway is still undergoing initial methodological design on the early phase.                   
 
4.4.3 Assessment on Intelligential Development 
Based on the concepts of fundamental psychology, Battelle Developmental 
Inventory is defined as the measurement of developmental milestones allowing adaptations 
for specific disabilities, including cognitive skills, adaptive skills, motor skills, 
communication skills, and personal-social development, whereas Vineland Adaptive 
Behavior Scale is described as the measurement of adaptive behaviors associated with the 
ability to cope with environmental changes, including fundamental socialization skills, 
communication skills, basic motor skills, and daily living adeptness. So, based on these 
psychological definitions, a combination of Battelle Developmental Inventory-2 and Vineland 
Adaptive Behavior Scale-2 have been selected as the primary criteria to evaluate the potential 
improved level of intelligential development on G500-treated patients versus the 
G500-untreated ones under this particular circumstance.  
In Fig.22 (A), the baseline values of intelligence-associated psychological 
behaviors have been evaluated on two studied patients prior to the commencement of G500 
therapeutic intervention, and it has been revealed that the 26-month old patient displaying 
more significantly aggressive pattern of intelligence-related behavioral development then the 
24-month old patient in the majority of studied aspects except for fine motor whose level are 
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equivalently developed in both studied subjects, implying the possibility of age-dependent 
baseline shifting between studied patients on the measuring values in relation to intelligential 
development, which might act as a possible influential factor affecting the data quality of 
following studies.  
In Fig.22 (B), with the continual administration of G500 to one of the studied 
patients, in comparison with the untreated patient, the extent to which the psychological 
activities associated with the intelligential development are being virtually improved have 
been observed to be significant for self care and self concept, suggesting the gangliosides 
absorbed by the patients’ physiological system and utilized by their metabolic pathways from 
administered G500 might have been therapeutic in terms of facilitating the intelligential 
developments on self-related behaviors. However, only minor/none degree of behavioral 
improvements have been observed for aspects like adult interaction, expressive 
communication, fine motor, attention/memory, and perception/concepts, which might be 
caused by shifting on the baseline values at the pretreated stage. Surprisingly, the treated 
patient has been found to possess diminished level of receptive communication development 
compared to the untreated one, which is not consistent with the psychological patterns 
determined by other intelligential behaviors.    
 
4.5 Conclusion 
In the present work, we proposed a therapeutic intervention strategy based on 
oral administration of exogenous gangliosides to cure an inherited neurological disorder, 
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Ganglioside GM3 Synthase Deficiency, and established a systematic approach to 
biochemically evaluate the clinical behaviors of studied patients as well as the therapeutic 
effectiveness of the proposed therapy from many different aspects. From the clinical 
perspective, compared to untreated patients suffering severe physical and mental 
developmental stagnation, treated patients displayed significantly improved physical 
development and moderately improved psychological behavior as the treatment progresses, 
implying the ultimate uptake and utilization of the administered gangliosides by their 
physiological systems to replace the missing gangliosides from their metabolic pathways. 
From the analytical perspective, the plasma levels of circulating monosialogangliosides 
determined by LC/MS/MS from treated patients showed inconsistent patterns of fluctuation 
compared to baseline values determined from the pre-treated stage, suggesting the possibility 
of rapid metabolism of exogenous gangliosides might have undergone to downstream 
derivatives following their physiological absorption. 
By principle, plasma level of free GM3 acts as a direct reflection on the 
abundance of GM3 being integrated onto the cell membrane lipid bilayer as a physiological 
equilibrium must be existing between the unbound GM3 presenting in the blood circulation 
and bound GM3 incorporated to the cell membrane. In the complete absence of endogenous 
unbound GM3 in patient blood circulation in response to enzymatic dysfunction on GM3 
synthase, the level of bound GM3 being integrated into the glycolipid-enriched microdomain 
is expected to be equivalently absent from the cell membrane. Additionally, as GM3 serves as 
a universal and indispensable synthetic precursor for the de-novo biosynthesis of a- and 
b-ganglioside series, its endogenous absence usually causes the premature biosynthetic 
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termination of all GM3-derived downstream metabolites, especially those more complex 
gangliosides such as GD1a, GD1b, GT1a, and GT1b, all of which are fine molecular 
regulators in modulating cell proliferation, differentiation, migration, and adhesion during the 
maturation and maintenance of physiological and psychological systems, leading to the 
substantial alternations on the composition and organization of lipid-anchoring scaffold 
within the lipid raft and thus the significant disruptions on the ordinary functionalities of 
glycolipid-enriched microdomain in orienting the incorporated cell surface receptor tyrosine 
kinases towards the incoming ligands for transmitting the extracellular biological signaling 
into the cytoplasmic machinery. Based on previous studies, although it has been revealed that 
increased GM3 level in general up-regulates the inhibitory effects on the dimerization and 
autophosphorylation of the majority of receptor tyrosine kinases, whereas the increased level 
of its downstream derivatives, including GD1a, GD1b, GT1a, and GT1b, has also been found 
to be able to effectively activate those receptors by inducing the dimerization of the 
extracellular ligand-binding domain and the subsequent autophosphorylation of the 
cytoplasmic tyrosine kinase domain at low concentration or complete absence of specific 
ligands, suggesting distinctive regulatory roles of various ganglioside species. As a result, the 
overall impact of the metabolic disruptions by genetic defects, as demonstrated in the case of 
GSD patients, on balancing act between the molecular interactions of GM3 and its 
downstream more complex metabolites with individual receptor tyrosine kinases seems to be 
the primary driving force accounted for the pathogenesis of GSD as well as the eventual 
development of severe symptoms associated with the disease, which could be better 
illustrated by analyzing results obtained from clinical studies in conjunction with discoveries 
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reported by other studies as following. 
Recently, previous study has demonstrated that GD1a, one of the major 
downstream metabolites of GM3 from the biosynthetic pathway of a-series ganglioside that 
are expected to present in the blood circulation of patients undergoing G500 treatment, is 
capable of stimulating the proliferation of normal human dermal fibroblasts by promoting the 
EGFR dimerization through a ligand-independent mechanism and hence enhancing the 
autophosphorylation of the cytoplasmic tyrosine kinase domain of EGFR, leading to the 
subsequent activation of Ras and Raf, which in turn causes the EGFR-mediated activation of 
mitogen-activated protein kinase (MAPK) pathway [9]. Moreover, alternative study has also 
discovered that GD1a facilitates the differentiation of human mesenchymal stem cells to 
osteoblasts primarily by stimulating the autophosphorylation of cytoplasmic tyrosine kinase 
domains from extracellular signal-regulated kinases (ERK), mitogen-activated protein kinase 
(MAPK), and epidermal growth factor receptor (EGFR). In the presence of decreased level of 
GD1a through knockdown of ST3GalⅡ, the enzyme that catalyzes the synthesis of GD1a 
from GM1, by shRNA transfection, inhibitory effects caused by reduced phosphorylation of 
ERK, MAPK, and EGFR has been observed during the differentiation [10], implying one of 
the potential molecular mechanisms by which the physical developments of treated patients 
are clinically improved by acquiring certain amounts of circulating GD1a through the 
metabolism of absorbed exogenous GM3 and stimulating the activity of EGFR and its 
downstream signaling cascades upon its interaction with GD1a. 
In addition, it has been revealed that the over-expression of gangliosides, 
especially GD1b and GT1b, significantly enhances the proliferation of a rat 
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pheochromocytoma cell line (PC12) by transfecting the cell line with ganglioside GD3 
synthase gene. The increased levels of GD1b and GT1b, both of which are major downstream 
metabolites of GM3 from the biosynthetic pathway of b-series gangliosides that are expected 
to present in the blood circulations of treated patients, stimulate the proliferative event by 
continuously phosphorylating the tropomyosin receptor kinase A (TrkA) and constitutively 
inducing a conformational change of TrkA to form a active dimer, leading to elevated 
activation of the downstream ERK1/2 and PI3K/Akt pathways even in the absence of nerve 
growth factor (NGF) [11], suggesting an alternative molecular mechanism by which the 
significant improvements on physical development of treated patients in comparison with 
control patients are accomplished partially through the cell proliferation stimulated by 
triggering an continual dimerization of Trkt and activation of ERK1/2 and PI3K/Akt 
pathways with elevated levels of GD1b and GT1b.         
Furthermore, mounting evidence has also illustrated that the hepatocyte growth 
factor receptor c-Met displayed a ganglioside-dependent manner of activation in breast 
cancer cells by expressing the GD3 synthase in MDA-MB-231 breast cancer cells to induce 
the cell surface accumulation of b- and c-series gangliosides, including GD3, GD2, and GT3, 
all of which are practically accessible to the patients receiving ongoing oral administration of 
G500. Among these complex gangliosides, GD2 was found to be extensively implicated in 
the activation of c-Met as well as the subsequent activation of MEK/ERK and PI3K/Akt 
signaling pathways, leading to enhanced cell migration and proliferation, which is further 
confirmed with the competition assays by competitively blocking the oligosaccharide moiety 
of GD2 from interacting with the c-Met using anti-GD2 mAb and thus inhibiting the 
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phosphorylation of c-Met. Comprehensively, markedly reduced levels of GD2 biosynthesis 
and c-Met phosphorylation and the reverse proliferative phenotypes were observed as the 
GD2 synthase gene was silenced by siRNA transfection [12-14], indicating the potential 
regulatory role of GD2 in facilitating the physical and mental development of treated patients. 
Finally, it has been evident that ganglioside enrichment in human umbilical vein 
vascular endothelial cells (HUVEC) can sensitize the vascular endothelial growth factor 
receptor (VEGFR) by inducing the VEGFR dimerization and auto phosphorylation at 
sub-threshold level of VEGF, causing the subsequent activation of VEGFR/PKC/MAPK and 
VEGFR/PI3K/MAPK pathways, which in turn leads to the markedly potentiated cell 
proliferation and migration [15]. In parallel studies, pre-incubation of HUVEC with 
exogenous GD1a prior to the addition of VEGF has also been found to substantially 
up-regulate the VEGF-induced cell proliferation and migration [16], shedding a new light on 
elucidating the underlying mechanism by which the clinical symptoms of GSD on treated 
patients are being gradually relieved in response to the G500 therapeutic intervention 
strategy.     
Overall, this oral administration-based therapeutic intervention strategy 
demonstrates certain potentials in terms of curing this infantile-onset clinical condition, 
especially for affected newborns that typically have short exposure to the premature 
ganglioside biosynthetic termination and endogenous depletion. Since this is the first study to 
use dairy-originated gangliosides to treat a metabolic defect and assess the bioavailability and 
metabolism of orally administered gangliosides in humans, we believe that this therapeutic 
strategy might serve as a breakthrough for treating this devastating condition. Moreover, as 
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gangliosides’ neurotrophic and neuritogenic effects have already been demonstrated in 
various neurodegenerative disorders, such as Parkinson’s disease and Alzheimer’s disease, 
the therapeutic implications of this study might be much broader. Considering the 
gangliosides in our study are obtained from milk and given orally, the therapy could fall into 
the category of nutritional supplementation, which might dramatically accelerate its 
implications in all ganglioside-related neurological conditions. Undoubtedly, this study sheds 
a new light on fundamentally understanding the physiological and pathological functions of 
gangliosides in human brain.          
 
4.6 Future Direction 
In this study, we implemented a clinical study in attempts to treat an inherited 
metabolic disorder associated with ganglioside GM3 biosynthesis by using a therapeutic 
intervention strategy based on oral administration and established a corresponding assessment 
system to biochemically evaluate the clinical response of studied patients as well as the 
therapeutic effectiveness of the therapy. Based on the results we collected from the clinical 
trial, the treated patients in general displayed positive feedbacks in terms of relieving the 
severity of the developing symptoms from the clinical standpoint, demonstrating the potential 
of this therapeutic intervention strategy in treating this particular condition. However, from 
the analytical standpoint, the concentration values of several major metabolic intermediates 
on the pathway in the plasma circulation of studied patients showed irregular variation 
around the baseline value in response to the therapy progression, signifying that minor 
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quantity of administered molecules might have been obtained from the absorption event 
during delivery and the rapid influx and efflux of absorbed molecules through the whole 
metabolic pathway, both of which could be attributed to inefficient delivery and inconsistent 
absorption pattern of administered molecule in relation to the complexity of oral 
administration. As a result, the conditions of oral administration associated have to be further 
optimized to improve the delivery as well as absorption efficiency and thus increase the 
bioavailability of the administered molecule for being able to observe more confident, 
promising, and convincing clinical outcomes from the ongoing clinical trial.  
By principle, oral administration is usually well-known as the most complicated 
drug delivery system with the most unpredictable outcome as the orally administered 
molecule might be subject to all possible kinds of physiological modifications and 
degradations associated with digest system prior to its entry into the blood circulation and 
ultimate reachout to the targeted site for interaction. Based on our discussion on gangliosides’ 
molecular structure from the previous chapter, the only possible site available for covalent 
modification on their structures is the protruding carboxylic acid group on the sialic acid 
residue Neu5Ac, which might be subjected to modifications like esterification, 
decarboxylation, and amidation catalyzed by various enzymes as they are traveling through 
the different physiological system. Therefore, the co-administration of synthetic carboxyl 
group-containing structural analog, GM4 for instance, in combination with G500 formula is 
necessitated to substitute administered gangliosides from undergoing possible structural 
modifications and thus preserve them to proceed into the circulations in their original 
structure, enabling them to further participate into the metabolic pathway and exert their 
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normal biological functions to compensate for the physiological damage caused by longterm 
GM3 deficiency.  
In addition, as gangliosides are featured by carbohydrate moieties made up with 
monosaccharide building blocks through either α-1, 3- or α-1, 4-glycosidic linkage except for 
Neu5Ac whose linkages are usually α-2, 3- or α-2, 4-glycosidic bond, stomach who has the 
capability of secreting the gastric acid and reducing the PH to as low as 2 during the digestion 
could potentially act as the primary organ facilitating the degradation of administered 
gangliosides and breaking them down into individual monosaccharide units before they are 
absorbed by the circulations due to the fact that glycosidic bonds are extremely sensitive and 
fragile to hydrolysis catalyzed by high concentration of acids. Hence, in order to preserve 
administered gangliosides to enter the circulations in their biological active form, the 
secretion of gastric acid by the stomach has to be properly inhibited by synthetic inhibitors 
specifically targeting the gastric acid secretion pathway to minimize their possible 
degradation while the oral administration is undertaken. Currently, two main classes of 
gastric acid secretion inhibitors have been made available to the market, histamine 
H2-receptor antagonists and proton pump inhibitors, both of which are FDA approved drugs 
to treat disorders associated with gastric acid secretion. Mechanistically, the histamine 
H2-receptor antagonists act by reversibly blocking the action of histamine to its receptor, a 
stimuli released by neighboring mucosal cells to stimulate the secretion of gastric acid in 
anticipation of a meal or when the food enters the stomach, which is capable of moderately 
elevating the pH value in the stomach by approximately one unit. While the proton pump 
inhibitors act by inactivating the final step in acid secretion - the transportation of proton ions 
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from the parietal cells to the lumen of the gastric glands, which has a more potent and longer 
lasting effect on acid secretion than the histamine H2-receptor antagonists, allowing larger 
amount of administered gangliosides to survive through gastric digestion and longer time 
window for the subsequent absorption to take place in the intestine. Expectedly, with the 
co-administered proton pump inhibitors to reduce the secretion of gastric acid, more 
exogenous gangliosides from G500 would get thoroughly preserved through the gastric 
digestion for later absorption, and thus their bioavailability in the blood circulation would be 
increased significantly.  
Lastly, since gangliosides are predominantly localized at the outer leaflet of cell 
plasma membrane in a special configuration where the hydrophobic ceramide portion is 
embedded inward into the plasma membrane for stable anchoring and the hydrophilic 
carbohydrate moiety is protruding outward into the extracellular matrix for accessible 
interaction, their carbohydrate moieties are usually conferred with pretty high degree of 
protein-binding affinity via non-covalent interactions like hydrogen bonding and electrostatic 
interaction, which possibly prohibits them from being taken up by the tissues or cells around 
the circulations as the huge size of ganglioside-protein complex makes it stand little chance 
of penetrating through and being settled down onto the cell membrane. More importantly, the 
dissociation of this ganglioside-protein complex could be an unfavorable kinetic process, 
which impedes the release of gangliosides into their free molecular forms and requires the 
application of a carrier vehicle to create an isolated protein-free environment to physically 
prevent the interaction from happening between gangliosides and proteins. Therefore, the 
enriched gangliosides purified from cow or bovine milk are ought to be formulated into a 
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protein-free lyophilized powder and encapsulated into carrier vehicle along with proton pump 
inhibitors as well as carboxyl group-containing structural analogs for administration to 
increase the efficiency of preservation and reduce the occurrence of undesirable 
bindings/interactions with other proteins during the absorption. 
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